The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma

Sathyen A. Prabhu 1,2,†, Omar Moussa 1,2,†, Wilson H. Miller, Jr. 1,2,3,4,5 and Sonia V. del Rincón 1,2,3,4,*

1 Division of Experimental Medicine, McGill University, 1001 Decarie Boulevard, Montreal, QC H4A 3J1, Canada; sathyen.prabhu@mail.mcgill.ca (S.A.P.); omar.moussa@mail.mcgill.ca (O.M.); wilson.miller@mcgill.ca (W.H.M.J.)
2 Lady Davis Institute, Jewish General Hospital, McGill University, 3755 Côte Ste-Catherine Road, Montreal, QC H3T 1E2, Canada
3 Department of Oncology, McGill University, 845 Sherbrooke St W, Montreal, QC H3A 0G4, Canada
4 McGill Centre for Translational Research in Cancer (MCTRC), McGill University, 3755 Côte Ste-Catherine Road, Montreal, QC H3T 1E2, Canada
5 Rossy Cancer Network, McGill University, 1980 Sherbrooke Ouest, #1101, Montreal, QC H3H 1E8, Canada
* Correspondence: soniavictoria.delrincon@mcgill.ca
† These authors contributed equally to this work.

Received: 11 May 2020; Accepted: 29 May 2020; Published: 5 June 2020

Abstract: Melanoma is a type of skin cancer that originates in the pigment-producing cells of the body known as melanocytes. Most genetic aberrations in melanoma result in hyperactivation of the mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. We and others have shown that a specific protein synthesis pathway known as the MNK1/2-eIF4E axis is often dysregulated in cancer. The MNK1/2-eIF4E axis is a point of convergence for these signaling pathways that are commonly constitutively activated in melanoma. In this review we consider the functional implications of aberrant mRNA translation in melanoma and other malignancies. Moreover, we discuss the consequences of inhibiting the MNK1/2-eIF4E axis on the tumor and tumor-associated cells, and we provide important avenues for the utilization of this treatment modality in combination with other targeted and immune-based therapies. The past decade has seen the increased development of selective inhibitors to block the action of the MNK1/2-eIF4E pathway, which are predicted to be an effective therapy regardless of the melanoma subtype (e.g., cutaneous, acral, and mucosal).

Keywords: melanoma; MNK1; eIF4E; translation; immunotherapy

1. Classification of Melanoma Molecular Subtypes

Melanoma is the deadliest of all skin cancers and has its origins in the pigment-producing cells of the body known as melanocytes. Specific mutations in melanoma may be more predominant within particular pathological subtypes. For instance, The Cancer Genome Atlas (TCGA) defined three genomic subtypes of cutaneous melanoma based on the mutation status of BRAF, NRAS, NF1, and a fourth subgroup termed triple wild-type [1]. Acral and mucosal melanomas, on the other hand, harbor distinct mutations, namely in the gene encoding the c-KIT receptor tyrosine kinase (RTK) [2], while uveal melanomas often present with mutations in GNAQ/11 [3].

2. Frequently Occurring Mutations in Melanoma and Molecular Significance

BRAF mutations are mostly caused by single nucleotide substitutions, of which approximately 90% occur at codon 600, where a valine residue is swapped with glutamic acid (BRAF\textsuperscript{V600E}) [4].
This specific mutation results in the constitutive activation of the BRAF oncoprotein and sustained activation of the MEK/ERK pathway (Figure 1), while also conferring insensitivity to negative feedback regulation of the mitogen-activated protein kinase (MAPK) pathway [5]. BRAF mutations account for approximately 52% of cutaneous melanoma mutations, compared to only 6% in mucosal melanoma [6]. While BRAF mutations are the most prevalent in cutaneous melanoma, NRAS mutations display more aggressive phenotypes with increased mitotic rate, thicker primary tumors, and poorer prognosis [7,8]. Mutations in NRAS account for approximately 28% of cutaneous melanoma, of which more than 80% harbor a glutamine-to-leucine substitution (NRASQ61L), thus compromising the intrinsic GTPase activity of NRAS and increasing its GTP-bound form [6]. GTP-bound Ras proteins activate the downstream effectors RAF and phosphoinositide 3-kinase (PI3K) (Figure 1). The abundance of Ras in its GTP-bound form also depends on the presence of the tumor suppressor NF1, a Ras GTPase-activating protein (GAP) (Figure 1). Mutations in the tumor suppressor NF1 are observed in approximately 14% of cutaneous melanoma, of which 63% are characterized by a loss-of-function [6]. Tumors that are negative for BRAF, NRAS, and NF1 mutations are termed triple wild-type and include a wide array of altered genes that may play a role in tumorigenesis. For instance, mutations in KIT, the gene encoding the c-KIT receptor, account for 22% of triple wild-type tumors. Oncogenic alterations in KIT include translocations within exons 11 and 13 (L576P and K624E, respectively), thus resulting in constitutive activation of c-KIT and subsequent activation of the PI3K/AKT and MAPK pathways [9] (Figure 1).

Figure 1. Schematic of the MNK1/2-eIF4E axis. The red stars on the NRAS, RAF, and NF1 indicate the three common subtypes of cutaneous melanoma. Mutations in BRAF result in the hyperactivation of the mitogen-activated protein kinase (MAPK) pathway while mutations in NRAS or NF1 result in the hyperactivation of both MAPK and phosphoinositide 3-kinase (PI3K) pathways. Activating mutations in c-KIT result in hyperactivation of Ras and downstream effector pathways. Signaling down the MAPK pathway results in the activation of MNK1/2 and signaling down the PI3K/Akt pathway results in the hyperphosphorylation of 4E-BP and the resultant release of eIF4E to associate with eIF4G. MNK1/2 bind to eIF4G and phosphorylate eIF4E at Ser209. This results in enhanced translation of certain mRNAs. MNK1 and MNK2 may also be phosphorylated by p38 through stress-mediated signals.
3. Targeted Therapies for Specific Molecular Subtypes in Melanoma

Several therapies have been designed to target the most frequent mutations in cutaneous melanoma. Drugs inhibiting the kinase activity of BRAFV600E include vemurafenib, dabrafenib, and encorafenib. Vemurafenib was the first Food and Drug Administration (FDA)-approved BRAFV600E inhibitor following a phase-III randomized clinical trial that was conducted in 675 patients [10]. In that study, treatment of advanced melanoma patients with vemurafenib improved overall survival and progression-free survival when compared to dacarbazine, a chemotherapeutic agent that was the first-line therapy approved for metastatic melanoma since 1972 [11]. While monotherapy using BRAF inhibitors appeared to be an exciting alternative to chemotherapy, responses were often temporary with resistance developing at a median of approximately seven months [12]. Resistance mechanisms to BRAF inhibition include reactivation of the MAPK pathway and activation of the PI3K/Akt pathway in approximately 70% and 22% of advanced tumors, respectively [13]. Furthermore, BRAF inhibition can paradoxically activate wild-type CRAF [14], and continued monotherapy with vemurafenib following the onset of resistance may further support tumor progression [15,16]. Thus, numerous combination therapies with MEK inhibitors were proposed to prevent or delay the onset of resistance to BRAF inhibition [17–19]. A number of resistance mechanisms to the combination therapy of BRAF and MEK inhibition have been characterized (reviewed in [20]). Some of these include BRAF amplification, oncogenic NRAS mutations, and MEK1/2 mutations [20], in addition to a PAX3-mediated upregulation of MITF in approximately 80% of melanoma during early stages of resistance [21]. Moreover, NF1 loss of function may also confer resistance to MEK and BRAF inhibition [22]. Loss of other tumor suppressors such as PTEN, TP53, or CDKN2A may also account for the increased aggressiveness of BRAF-mutated tumors. For instance, co-occurrence of BRAFV600E and loss of PTEN manifest in approximately 20% of melanomas and show increased metastatic potential [23]. While several options are available for the treatment of BRAF-driven melanoma, limited targeted therapies are available for NRAS-mutated tumors, given the difficulties in directly targeting the Ras GTPase [24]. While inhibiting farnesylation of Ras may prevent its translocation to the plasma membrane and forestall activation of downstream effectors, farnesyltransferase inhibitors (FTIs) have shown no clinical benefit in advanced melanoma [25]. On the other hand, binimetinib, a MEK1/2 inhibitor, has shown improved progression-free survival when compared to dacarbazine in patients with advanced melanoma who harbor NRAS-mutations [26]. Conversely, resistance to MEK inhibition in NRAS-mutant melanoma may be mediated through activation of the anti-apoptotic cAMP/MITF/Bcl-2 pathway [27]. Other inhibitors of the MAPK pathway, including pan-RAF and ERK inhibitors, have been shown to decrease tumorigenesis in NRAS-mutated tumors [27–29]. In c-KIT-mutant melanoma, several RTK inhibitors have been tested in the clinical space, with comparable overall response rates (ORR) reported for imatinib (23.3%) and nilotinib (26.2%), and slightly lower rates for dasatinib (18.2%) [30–32]. In a phase-II clinical trial conducted in 28 patients with melanoma harboring c-KIT mutations or amplifications, treatment with imatinib yielded a durable response rate of 16%, with responses lasting more than one year [33]. More recently, ponatinib has been shown to exhibit greater potency than imatinib in inhibiting tumor growth in melanomas harboring KIT mutations, likely because of an increased ponatinib–KIT affinity [34]. Whereas targeted therapy against c-KIT has been effective in treating gastrointestinal stromal tumors (GIST) [35], its inhibitory activity is far less impressive in c-KIT-mutant melanoma, and responses tend to be short lived, with a median time to progression of three months [33]. Once again, mechanisms of resistance hamper the therapeutic benefits of RTK inhibitors, including amplification or overexpression of KIT [36], other simultaneous activating alterations in NRAS [36], and secondary mutations in the activation loop of c-KIT [37]. Furthermore, the L576P mutation in KIT, represented in approximately 34% of KIT mutations, confers poor sensitivity to imatinib in GIST [38]. In the context of melanoma where the L576P is the most common KIT mutation, patients show increased sensitivity to dasatinib [39]. Melanoma cells expressing dual activating mutations in KIT (e.g., L576P/T670I or A829P) while being resistant to imatinib, nilotinib, and dasatinib, did exhibit increased sensitivity to dual inhibition of the MAPK and PI3K pathways [37].
3.1. Rationale for Targeting the MNK1/2-eIF4E Axis in Cancer

Current targeted therapies in melanoma generally exhibit limited clinical efficacy, given the ability of tumors to develop resistance mechanisms [20]. One way that cancer cells adopt resistance is by hijacking the function of downstream effector proteins, sometimes involving the activation of parallel signaling pathways [40]. For instance, a convergence point downstream of the MAPK and the PI3K/AKT/mTOR pathways, arguably two of the most important signaling pathways in melanoma, is the eukaryotic initiation factor 4F (eIF4F) complex, which regulates mRNA translation initiation (Figure 1). Components of the eIF4F complex include (1) eIF4A, a DEAD-box RNA-helicase responsible for unwinding mRNA secondary structures, (2) eIF4E, which binds the 7′methylguanosine cap (m^7G) at the 5′ end of mRNAs, and (3) eIF4G, a scaffold protein that interacts with eIF4E and eIF4A. The PI3K-AKT/mTOR pathway signals directly to eIF4E via the phosphorylation of eIF4E-binding proteins (4E-BPs). Hypophosphorylated 4E-BPs sequester eIF4E from binding to eIF4G, thus preventing formation of the translation initiation complex, while phosphorylation of 4E-BPs by mTOR releases eIF4E and activates translation [41] (Figure 1). Translation of specific subsets of mRNAs, including those encoding oncoproteins, is further activated via the phosphorylation of eIF4E by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (MNK1/2), downstream of MAPK activation [42]. MNK1/2 are the only kinases responsible for phosphorylating eIF4E on Ser209 [43,44].

Increased levels of eIF4E are associated with poor prognosis in many cancer types including breast [45], melanoma [46], prostate [47], gallbladder [48], colorectal adenocarcinoma [49], and hepatocellular carcinoma [50] and correlate with advancing tumor grade in squamous cell carcinoma [51] and esophageal cancer [52]. Moreover, the phosphorylation of eIF4E is tightly regulated and plays an important role in cell proliferation and metastasis [53,54]. Increased phospho-eIF4E levels is an independent prognostic factor in astrocytomas [55], NSCLC [56], and nasopharyngeal carcinoma [57], while also being associated with disease progression in melanoma [58] and prostate cancer [59]. Increased levels of phospho-eIF4E were also observed in gastric and colorectal cancers [60], whereas overexpression of MNK1 in epithelial ovarian cancer correlates with phospho-eIF4E levels and poor clinical outcome [61]. Our research has shown that KIT-mutant melanoma patients have increased levels of MNK1 and phospho-eIF4E, and in breast cancer increased levels of p-MNK1 were associated with high-grade ductal carcinoma in situ [62,63]. Moreover, while upstream components of the MAPK and PI3K pathways often show a heterogeneous expression pattern in tumors, the expression of phospho-eIF4E and phospho-4E-BP are more diffuse within the tumor and are overexpressed in breast cancer [64]. While eIF4E is required for cap-dependent mRNA translation, a genetically engineered eIF4E haploinsufficient mouse prevented cellular transformation but maintained normal development [65]. MNK1/2 and phospho-eIF4E are also dispensable for normal murine development [42,59,62]. Thus, whereas using BRAF and MEK inhibitors in metastatic melanoma patients caused severe adverse events (reviewed in [66]), pharmacologically inhibiting MNK1/2 kinases represents a promising therapeutic option, as limited side-effects and toxicities are expected upon abrogation of MNK1/2 activity. Together, these previously published works support the MNK1/2-eIF4E axis and eIF4F complex as promising therapeutic targets in cancer.

3.2. Structural and Functional Differences Between MNK1/2 Isoforms

MNK1 and MNK2 are serine-threonine kinases encoded by two genes, MKNK1 and MKNK2, respectively. In humans, each MKNK may be alternatively spliced into “a” and “b” isoforms, while in mice only the full length, or “a”, isoform has been reported [67,68] (Figure 2). Human MNK1 and MNK2 are approximately 94% identical to their mouse counterparts [68,69]. Shared among all isoforms is a polybasic sequence (PBS) on the N-terminus that confers affinity for eIF4G1/2 and importin α, thus also functioning as a nuclear localization signal (NLS) [44,70,71]. A decrease in the phosphorylation of eIF4E is observed when binding of eIF4G to MNK1 is abrogated [72]. The latter is in keeping with the role of eIF4G as a scaffold protein, bringing MNK1 and eIF4E into close proximity to ensure specific MNK isoforms, wherein a leucine-rich nuclear export sequence (NES) only features
in MNK1a, thus enabling CRM1 (exportin 1)-mediated nuclear export, and a MAPK-binding domain is exclusive to MNK1a and MNK2a [67,71,73]. A specific amino acid difference in the MAPK-binding motif between MNK1a (LARRR) and MNK2a (LAQRR) contributes, in part, to the preferential binding of p38 MAPK to MNK1a and ERK MAPK to MNK2a. For a comprehensive mapping of residues and motifs within MNK1 and MNK2 that account for preferential MAPK binding, refer to Parra et al. [74,75]. Human MNK1 and MNK2 proteins are phosphorylated on two threonine residues within the T-loop (Thr209/214) by ERK1/2 and p38 MAPKs in response to mitogenic- and stress-stimuli, respectively [75]. However, MNK2 shows a higher basal activity than MNK1, which may be explained by features in the C-terminus and the catalytic domain of MNK2 [70,74]. Similarly, MNK2b also displays a high basal activity, although to a lesser extent than MNK2a, whereas MNK1b exhibits a higher basal activity than MNK1a [67,70]. Basal phosphorylation of eIF4E by MNK2a/2b has been suggested to maintain the synthesis of proteins essential for cell survival [67].

![Figure 2. Schematic representation of the core features of human and murine mitogen activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2). In humans, MNK1 and MNK2 are spliced into “a” and “b” isoforms whereas in mice MNK1 and MNK2 are not spliced. NLS, nuclear localization signal; NES, nuclear export signal.](image)

A unique feature to MNK1/2 is the presence of a DFD (Asp-Phe-Asp) motif, contrary to other kinases in the same superfamily that possess a DFG (Asp-Phe-Gly) motif in the magnesium-binding loop [76]. This results in an unusual DFD-out, auto-inhibited conformation in which the phenylalanine residue flips into the ATP binding pocket hindering the accessibility of ATP [76]. The exclusivity of this domain to MNK1/2 makes it an appealing target for the development of selective inhibitors that stabilize MNK1/2 in its auto-inhibited form and prevent its kinase activity [77].

Expression of particular MNK isoforms may confer different effects on tumor progression. The proto-oncogene SRSF1 (also known as SF2/ASF) regulates MNK2 splicing, and is overexpressed in many human tumors including colon, thyroid, small intestine, kidney, and lung [78]. Overexpression of SRSF1 resulted in increased MNK2b and phospho-eIF4E levels, while decreasing MNK2a levels [78]. Importantly, increased levels of MNK2b splice isoform has been reported to mediate resistance to gemcitabine in pancreatic ductal adenocarcinoma [79]. While the MNK2b isoform has been suggested to possess pro-tumorigenic activity, MNK2a is thought to have tumor suppressive effects through phosphorylation, activation, and nuclear translocation of p38, thus causing stress-induced cell death [80]. In contrast, MNK1a and MNK1b have thus far been shown to possess pro-tumorigenic roles [81–83].

### 3.3. Differential Cellular Localization of MNK1ab and MNK2ab

The presence of an NLS in the N-termini of MNK1/2 and an NES within the C-terminus of MNK1a hints at yet to be uncovered biological functions for MNK1, MNK2, and their splice isoforms. Studies characterizing the splice variants of MNK1/2 have found different subcellular localization of the “a” and “b” isoforms [67,70]. MNK1a and MNK2a both predominantly localize to the cytoplasm, despite MNK2a lacking an NES [70]. The latter may be explained by the C-terminus of MNK2a impeding access to its NLS on the N-terminus, consistent with its decreased affinity for eIF4G [70].
On the other hand, MNK1b and MNK2b, which possess a shorter C-termini than the “a” forms, are devoid of an NES and show localization to the nucleus [67,70]. While both MNK1b and MNK2b also phosphorylate eIF4E [67,70], their presence in the nucleus suggests potential divergent functions from the “a” isoforms. MNK2b has been shown to colocalize with nuclear promyelocytic leukemia (PML) protein and eIF4E in the nucleus [70]. PML binds directly to eIF4E through the PML RING domain and reduces the affinity of eIF4E for the m^7G cap of mRNAs, thus decreasing the nucleocytoplasmic transport of cyclin D1 mRNA and reducing cyclin D1 protein levels [84,85]. These data suggest a role for eIF4E and its phosphorylation by MNK2b in regulating the cytoplasmic export of mRNA.

Interestingly, in nasopharyngeal carcinoma (NPC), astrocytoma, and epithelial ovarian cancer tissues, immunohistochemistry (IHC) was used to show expression of MNK1 or phospho-MNK1 in the nuclei, whereas phospho-eIF4E was more readily observed in the cytoplasm [55,57,61]. In non-small-cell lung carcinoma (NSCLC) patients, high levels of MNK2 were observed in the cytoplasm and correlated with phosphorylated eIF4E levels [86]. Importantly, high levels of MNK2 also correlated with poorer prognosis in NSCLC adenocarcinomas and stage III and IV patients [86]. In patient-derived melanoma samples, increased nuclear and cytoplasmic levels of total and phosphorylated eIF4E has been observed, and high levels of phosphorylated eIF4E were correlated with poor prognosis [58]. Further investigation will be required to determine whether MNK1/2 in the nucleus has yet to be identified substrates, and in turn whether we can better understand the significance of the nuclear localization of MNK1/2 isoforms in tumors.

3.4. Identified Substrates of MNK1/2

Despite eIF4E being the only confirmed in vivo substrate of MNK1/2, these two kinases may phosphorylate additional proteins to perform diverse functions. Cytosolic phospholipase A2 (cPLA2) has been suggested to play an important role in tumor angiogenesis and may confer resistance to radiation therapy [87]. Hefner and colleagues reported that MNK1 along with other p38-regulated protein kinases (PRAK1 and MSK1) phosphorylate cPLA2 on serine 727 in vitro and express a dominant negative MNK1 blocked arachidonic acid (an omega-6 fatty acid) release by cPLA2 [88]. Furthermore, the polypyrimidine tract-binding protein (PTB)-associated splicing factor (PSF) has also been shown to be phosphorylated by MNK1 on serines 8 and 283 in vitro [89]. PSF along with p54^nrb may play a role in binding AU-rich elements (ARE)-containing mRNAs, such as tumor necrosis factor-α (TNFα). This study also demonstrated that MNK1/2 inhibition decreased binding of PSF to TNFα mRNA [89]. PSF is associated with poor prognosis in ER^+ breast cancer cells, and knockdown of PSF results in a marked reduction of proliferation and increased apoptosis in colon cancer cells [90–92]. Another study by Buxade and colleagues identified MNK1 as a potential regulator of tumor necrosis factor-α (TNFα) expression through the phosphorylation of hnRNP A1, an ARE-binding protein [93]. hnRNP A1 has been shown to play diverse roles in cancer progression, namely by inducing epithelial-to-mesenchymal transition (EMT; a process by which tumor cells acquire invasive and metastatic properties) in gastric cancer [94,95]. Moreover, two studies have identified Sprouty 2 (Spry2) as an in vitro substrate of MNK1, whereby phosphorylation of Spry2 on serines 112 and 121 stabilizes the protein. Spry2 acts as a negative feedback regulator of RTK signaling by antagonizing growth factors [96,97]. However, Spry2 also possesses pro-tumorigenic effects by triggering increased proliferation in glioblastoma and metastasis in rhabdomyosarcoma [98,99].

4. Translational Targets of the MNK1/2-eIF4E Axis

Phosphorylation of eIF4E by MNK1/2 kinases is proposed to enhance the translation of a specific subset of mRNAs that encode proteins with roles in cell survival, invasion, and metastasis [59] (Figure 3). It is important to emphasize that regardless of the controversy surrounding the affinity of phospho-eIF4E for the m^7G cap [100–103], an overwhelming body of literature supports that the phosphorylation of eIF4E is essential for its pro-oncogenic and pro-metastatic effects [53,54,58–60,62,104]. Furic and colleagues showed that immortalized mouse embryonic fibroblasts (MEFs) harboring
a non-phosphorylated eIF4E (eIF4E<sup>S209A/S209A</sup>) are resistant to Ras-induced transformation, and their translation of specific mRNAs is reduced when compared to Wild-Type (WT) MEFs [59]. These include the chemokine CCL2, pro-invasive factors matrix metalloproteinases 3 and 9 (MMP3 and MMP9), baculoviral IAP repeat-containing protein 2 (BIRC2), and the vascular endothelial growth factor C (VEGFC) [59]. The authors also attributed the decreased expression of these proteins to the ability of the mutant mice to be resistant to PTEN loss–induced prostate cancer [59]. Subsequent studies showed that cells lacking phospho-eIF4E were unable to efficiently translate SNAI1 and MMP3 and resisted undergoing EMT [105]. Moreover, when MNK1/2 were knocked down in KIT-mutant acral melanoma cells, their ability to translate SNAI1 and CCNE1 was compromised and their invasive and metastatic properties reduced [62]. Another study highlighted the importance of phospho-eIF4E in promoting the post-translational regulation of CTNNB1 (encodes β-catenin) in chronic myelogenous leukemia (CML) cells and, thereby, preventing the rise of therapy-resistant stem cells [106]. These studies highlight the contribution of the MNK1/2-eIF4E axis in promoting oncogenicity and invasion. Additional work has led credence to the idea that the phosphorylation of eIF4E also mediates drug resistance. For example, in ER<sup>+</sup> breast cancer tumors, the phosphorylation of eIF4E on Ser209 promotes tamoxifen-resistance through enhanced translation of RUNX2 [107]. Finally, although much of what we know about the role of the MNK1/2-eIF4E axis has been described in tumor cells, an accumulating body of work suggests an important contribution of this axis in cells of the tumor microenvironment. Pro-metastatic neutrophils isolated from eIF4E<sup>S209A/S209A</sup>-bearing mice also manifest a decreased protein expression of anti-apoptotic factors BCL2 and MCL1, implicating the role of phospho-eIF4E in creating an anti-tumor microenvironment [108].

Figure 3. Schematic highlighting the processes that are regulated by the MNK1/2-eIF4E axis. Tumor extrinsic processes are indicated by the yellow outer wheel and tumor intrinsic processes are indicated by the orange outer wheel. Proteins whose mRNA is affected by phosphorylation of eIF4E are in black.

5. Therapeutic Targeting of the Cap-Dependent Translational Machinery

Numerous strategies have been employed to abrogate the oncogenic effects of deregulated mRNA translation. The core proteins of the eIF4F complex are frequently overexpressed in a multitude of cancers including, but not limited to, skin and breast cancer [45,51,109,110]. Currently, inhibiting aberrant mRNA translation in neoplasia involves two treatment modalities: indirectly targeting upstream pathways that converge on the eIF4F complex or directly targeting components of the
eIF4F complex. Inhibiting upstream kinases that regulate translation encompasses deregulating the availability of free eIF4E and preventing its phosphorylation-dependent activity. Directly targeting the eIF4F complex aims at decreasing expression of eIF4E, obstructing the interaction between eIF4E and the 5’ cap, disrupting the formation of the eIF4F complex altogether, and inhibiting eIF4A. Emphasis of some of these treatment modalities in melanoma will be reviewed in the subsequent sections.

5.1. Directly Targeting the eIF4F Complex

Initial efforts at inhibiting oncogenic translation were geared towards decreasing eIF4E levels and function. Antisense oligonucleotides have been utilized to decrease the intracellular levels of eIF4E [111–114]. One such antisense anti-cancer drug candidate, LY2275796, has been tested in melanoma, with no evidence of effectiveness [115]. In the phase I clinical trial, LY2275796 was tested in multiple advanced cancers including melanoma, and while administration of LY2275796 at 1000 mg/kg was well-tolerated and was effective at decreasing overall eIF4E levels in tissues, no tumor response was observed [115]. eIF4E levels have also been shown to be regulated by miRNA. Specifically, an increase in miR-768-3p was inversely correlated with eIF4E levels [116]. Overexpression of miR-768-3p was associated with decreased eIF4E levels. The authors showed that the downregulation of miR-768-3p was due to the hyperactivation of the MAPK pathway, a hallmark frequently manifested in melanoma [116]. Targeted inhibitors against BRAF\textsuperscript{V600E} and MEK using PLX4720 and U0126, respectively, decreased the expression of eIF4E through upregulation of miR-768-3p [116].

5.2. Putting a Cap on eIF4E

While antisense oligonucleotides successfully decrease overall levels of eIF4E, their efficacy in the clinic remains in question. The oncogenic properties of eIF4E, when overexpressed, are dependent on its ability to bind the 5’ cap on mRNAs [117]. Cap analogs have been around for decades and were frequently used in in vitro biochemical assays [118]. However, their use in vivo was initially limited due to issues of cellular permeability and stability [119]. This led to the development of pro-drug versions of cap analogs, which are cell permeable and undergo intracellular processing to active forms [119]. Cap analogs competitively bind to eIF4E and block cap-dependent translation. One such compound, N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) is a pro-drug that is cell permeable and is converted into the active compound 7-benzyl guanosine monophosphate in cells [119,120]. While clinically untested, multiple groups have demonstrated the anti-neoplastic effects of 4Ei-1 in lung cancer, mesothelioma, and breast cancer [121–123]. However, their efficacy in melanoma remains untested.

5.3. Disrupting the eIF4E:eIF4G Interaction

As mentioned above, the formation of the eIF4F complex is contingent upon the amount of available or free eIF4E. Activation of the PI3K/Akt/mTOR pathway leads to the hyperphosphorylation of 4E-BPs, resulting in their release of eIF4E, which is in turn free to bind the 5’ mRNA cap and initiate the formation of the eIF4F complex through its interaction with eIF4G [124]. eIF4G, in its role as a scaffold protein, directly binds and stabilizes the association of eIF4E to the 5’ cap and recruits eIF4A and the eIF3-40S ribosomal subunit [125]. Hence, impeding the eIF4E:eIF4G interaction is a cogent mechanism to suppress cap-dependent translation. High-throughput screening of 16,000 compounds led to the discovery of the small molecule 4EGI-1, which inhibits the eIF4E:eIF4G interaction and cap-dependent translation [126,127]. Moreover, not only did 4EGI-1 prevent the association of eIF4E to eIF4G, it also enhanced the ability of 4E-BP to sequester eIF4E, thus reducing the amount of eIF4E available for mRNA translation [127,128]. 4EGI-1 demonstrated anti-neoplastic effects on melanoma cells both in vitro and in murine xenografts with a desirable toxicity profile [128,129]. More recently, SBI-756, another small-molecule inhibitor of the eIF4E:eIF4G interaction was identified [130]. Similar to 4EGI-1, SBI-756 promoted the sequestering of eIF4E by 4E-BPs [130]. Upon further characterization, it
was demonstrated that SBI-756 impaired eIF4F complex formation in melanoma cells and inhibited the growth of BRAF, NRAS, and NF1-mutant melanoma cell lines [130]. Furthermore, SBI-756 delayed the onset and decreased the incidence of NRAS-mutant melanoma in vivo [130]. Importantly, A375 melanoma cells that acquired resistance to BRAF inhibitors were comparably sensitive to SBI-756 as the parental cell line in vitro [130]. Concomitant administration of PLX4720 and SBI-756 in melanoma xenograft models mitigated the formation of BRAF-inhibitor-resistant tumors [130]. One critical aspect, not covered by the aforementioned study, was to investigate the effects of SBI-756 on invasion and metastasis, as 4EGI-1 can inhibit migration and invasion in vitro [131]. Thus, agents that repress the eIF4E-eIF4G interaction hold the promise of inhibiting high-risk melanomas that are inherently drug resistant, such as NRAS-mutant melanomas, or those with acquired resistance to therapy.

5.4. Inhibitors of eIF4A

eIF4A is frequently activated in neoplasia, either through mRNA overexpression or suppression of the tumor suppressor protein PDCD4 (programmed cell death 4), which competes with eIF4G for binding to eIF4A [109,132–134]. Hence, eIF4A is an attractive target for the development of small molecule inhibitors. Three families of compounds known to inhibit eIF4A include the flavaglines or rocaaglamides, pateamine A, and hippuristanol, all of which display potent anti-tumorigenic effects. Flavaglines are natural compounds that are isolated from plants in the genus Aglaia and have demonstrated anti-neoplastic effects, with neuro- and cardio-protective properties [135–138]. Flavaglines exhibit anti-neoplastic effects through inhibition of eIF4A [135]. Crystallographic studies revealed that flavaglines exhibit RNA sequence selectivity, “gluing” eIF4A onto polypurine sequences in mRNA [136]. Flavaglines have demonstrated inhibitory effects on the CRAF-MEK-ERK signaling pathway via direct inhibition of prohibitins 1 and 2 [137]. The flavagline silvestrol increases the ATPase, helicase, and RNA-binding ability of eIF4A. In doing so, it promotes eIF4A:mRNA interaction in a non-sequence dependent manner and prevents its association with the eIF4F complex [138,139]. In melanoma, silvestroil has been shown to inhibit cell proliferation through increased accumulation of cells in G2/M and promotes autophagy-induced apoptosis [140]. It has been shown to both overcome vemurafenib resistance in BRAF-mutant melanoma cells and prevent the rise of therapy-resistant melanoma persister cells [141,142]. Persister cells are a category of cells that are therapy-resistant and may be key in initiating tumor relapse and acquired resistance. Hence, preventing the expansion of persister cells is important in maintaining response to primary therapies. Silvestroil has also been shown to synergize with MEK inhibitors in multiple NRAS-mutant melanoma cell lines [143]. Recently, it was also shown that silvestroil exerted its anti-tumor effects by suppressing the expression of the immune checkpoint protein PD-L1, by repressing the translation of STAT1 mRNA [144]. A current hurdle in the clinical development of silvestroil as an anti-neoplastic agent is resistance mediated by overexpression of the ATP-binding cassette sub-family B1 (ABCB1) gene, which codes for the multidrug resistance protein P-glycoprotein (P-gp) [145]. However, researchers are developing compounds that are insensitive to multidrug resistance and demonstrate potent in vivo anti-neoplastic effects [138]. A new compound, FL3, was demonstrated to overcome BRAF-inhibitor resistance in murine models of melanoma [143]. Importantly, flavaglines have started to be tested in clinical trials. The flavagline eFT226 (Zotatifin) has shown efficacy in suppressing the translation of numerous oncogenes including FGFR1, FGFR2, and HER2 [146]. Notably, eFT226 significantly suppressed tumor growth in xenograft models harboring amplifications in FGFR1/2 and HER2, and is currently in a phase I/II clinical trial against advanced solid tumor malignancies (NCT04092673) [146,147].

Pateamine A, like silvestroil, increases the ATP hydrolysis, helicase, and RNA-binding activity of eIF4A [148]. However, unlike silvestroil, Pateamine A is not a substrate of P-gp-mediated drug efflux. It irreversibly and covalently binds eIF4A, and is therefore very cytotoxic in vivo [148]. Pateamine A exhibits powerful anti-tumorigenic effects in multiple cancers [149,150]. DMDA-pateamine A, a synthetic derivative of pateamine A, has demonstrated potent inhibition of growth of melanoma xenografts in nude mice with a desirable toxicity profile [150].
In stark contrast to silvestrol and pateamine A, hippuristanol allosterically inhibits eIF4A association with mRNA and its helicase activity in both free form, as well as when eIF4A is incorporated in the eIF4F complex [151]. While the research on hippuristanol in the context of melanoma remains limited, its effects on therapy-resistant melanoma persister cells are comparable to pateamine A and silvestrol [141].

PDCD4 is a tumor suppressor protein that competes with eIF4G and eIF4A and consequently inhibits translation initiation [133,134]. Upon phosphorylation by S6 kinase 1, PDCD4 is tagged by the SCFβTrCP ubiquitin ligase for proteasomal degradation, resulting in the release of eIF4A [133,152,153]. Therefore, increasing PDCD4 expression may provide an avenue for inhibiting oncogenic translation initiation. PDCD4 is negatively regulated by miR-21 [154]. Consequently, antagonism and the curcumin EF24 analog, which decrease the expression of miR-21, are being investigated for their ability to stabilize the expression of PDCD4. Downregulation of miR-21 in murine melanoma syngeneic grafts by these compounds correlated with increased expression of PDCD4 and led to the formation of smaller lung metastases and increased survival, compared to control mice [154–156].

5.5. Toggling the Regulation of eIF4E by Targeting Upstream Kinases

Inhibiting eIF4E-mediated mRNA translation by targeting upstream kinases involves either targeting mTOR or MNK1/2 kinases. Inhibitors that interfere with the kinase activity of mTOR aim to prevent the phosphorylation of 4E-BPs and subsequently promote eIF4E:4E-BP complexes, thereby preventing eIF4E from associating with mRNA and the eIF4F complex [157]. While this method is promising, and mTOR inhibitors do exert anti-neoplastic effects, the reality is complicated due to either insufficient inhibition of 4E-BP or through feedback loops [157,158]. mTOR inhibition leads to decreased S6 kinase 1 activity, which results in an increase in pro-survival and proliferative signals through PI3K/Akt signaling [158–161]. One mode to circumvent the limitations of mTOR inhibitors is to not only prevent eIF4E from associating with eIF4F, but to also prevent the phosphorylation of eIF4E.

As mentioned above, MNK1 and MNK2 are the only kinases able to phosphorylate eIF4E on serine 209, and numerous studies have demonstrated that this phosphorylation event is critical for its oncogenic effects [42–44,53,54,57–61,162,163]. Different flavors of MNK1/2 inhibitors are being developed and thoroughly investigated in numerous cancer models. These include ATP-competitive inhibitors and more recently MNK1/2 degraders and allosteric inhibitors of MNK1/2 [77,164]. The most widely tested MNK1/2 inhibitors, CGP57380 and cercosporamide, showed promise in early studies but suffered from significant off-target effects [54,165]. However, more selective MNK1/2 inhibitors are currently under development. In melanoma, MNK1/2 inhibitors were shown to attenuate growth of pulmonary metastases in murine syngeneic grafts [54]. Using CRISPR-Cas9 technology, we recently showed that BRAF-mutant melanoma cells devoid of MNK1 were less metastatic in an experimental model of lung metastasis [166]. Comparably, in an experimental model of metastasis, mice treated with SEL201, an ATP-competitive MNK1/2 inhibitor, formed significantly fewer lung metastases than vehicle-control treated mice [166]. Our group has shown that MNK1/2 inhibition using SEL201 blocks the progression of metastatic KIT melanoma, concomitant with suppression of eIF4E phosphorylation [62]. We have also shown that use of SEL201 in models of breast cancer is associated with decreased outgrowth of ductal carcinoma in situ and hindered invasive disease progression [63]. Recently, a group reported that SEL201 was also effective in suppressing the growth of acute myeloid leukemia (AML) progenitor cell lines and had no detrimental effects on normal hematopoietic progenitor cells [167]. MNK1/2 inhibitors are being tested as single agents but have also been demonstrated to synergize with other therapeutic agents. Specifically, combined MNK1/2 and MEK inhibition cooperatively killed NF1-mutant malignant peripheral nerve sheath tumor (MPNST) cells in vitro and in vivo [168]. In the context of chronic myelogenous leukemia (CML), combined BCR-ABL1 and MNK1/2 inhibition was more effective in suppressing in vivo tumor growth in a xenograft model than was a targeted inhibitor against BCR-ABL1 alone [169]. MNK1/2 inhibition has also shown promise in suppressing the growth and increasing the response to conventional therapy in AML [170,171].
Under the premise that eIF4E-mediated mRNA translation can be modulated by targeting upstream kinases, multiple studies have investigated the combinations of mTOR and MNK1/2 inhibitors. In multiple cancer types, the combined inhibition of mTOR and MNK1/2 enhanced their anti-tumor effects compared to either agent alone [172–176]. In these studies, however, MNK1/2 inhibition was achieved using the CGP57380, and due to its lack of specificity, these results need to be interpreted with caution. However, a recent study demonstrated that selective MNK1/2 inhibition using SEL201 in combination with the mTOR inhibitor rapamycin was synergistic in suppressing the growth of AML progenitor cell lines [167]. This combination treatment represents a promising new avenue, yet to be explored in melanoma.

Importantly, MNK1/2 inhibitors have entered clinical trials for the management of cancers. BAY1143269 is a MNK1/2 inhibitor from Bayer that is currently in phase I clinical trials against advanced or metastatic solid tumors [177,178]. eFT508 (Tomivosertib) is a highly selective MNK1/2 inhibitor in phase I/II clinical trials alone or in combination with the immunotherapeutic agent avelumab [179]. Results from a phase II clinical trial combining eFT508 with PD-L1 inhibitors in microsatellite stable colorectal cancer (MSS CRC) demonstrated robust target engagement with acceptable toxicity, and one patient achieved a partial response lasting almost eight months [179].

The effects of MNK1/2 inhibition are not limited to their anti-neoplastic effects on tumor cells. MNK1/2 inhibition has been shown to elicit desirable, anti-tumor responses in immune cells. MNK1/2 have long been known to be important regulators of soluble factors such as cytokines, chemokines, and growth factors (reviewed in [180]). Such soluble factors have important roles in tumor cells, but also help to shape the tumor microenvironment. In macrophages, the inhibition of MNK1/2 attenuated the production of pro-inflammatory cytokines such as TNF-α, IL-6, and monocyte chemo-attractant protein-1 [181]. Conversely, MNK1/2 inhibition in macrophages stimulated with multiple Toll-like receptor (TLR) agonists also enhanced the production of the anti-inflammatory cytokine IL-10 [181]. Similarly, in TNF-α-stimulated human neutrophils, MNK1/2 inhibition attenuated the secretion of CCL-3, CCL-4, and CXCL8, while the overall mRNA levels of these cytokines remained unchanged [182]. Importantly, the overexpression of MNK1, but not a dominant negative mutant version of MNK1, increased the production of these cytokines [182]. A recent study demonstrated that orthotopic injection of breast tumor cells into phospho-eIF4E deficient transgenic mice led to fewer lung metastases, compared to the same cells injected into wild-type mice [108]. This finding suggested a role for the phosphorylation of eIF4E in cells of the tumor microenvironment. Indeed, the authors showed that the phenotype was due to a decreased expression of the anti-apoptotic proteins BCL2 and MCL1 in pro-metastatic neutrophils [108]. Complementing the results observed in the phospho-eIF4E deficient mice, pharmacological inhibition of MNK1/2 using the less selective inhibitor merestinib, in tumor bearing mice, decreased the levels of neutrophils in the lung [108].

Numerous research groups have investigated the role of MNK1/2 kinases in T-cell development and function. Studies have also demonstrated that inhibition of MNK1/2 kinase activity decreased the production of IL-17 [183]. IL-17 is a pro-inflammatory cytokine produced by a subset of CD4+ T helper 17 cells (Th-17). In melanoma, the effects of Th-17 cells and IL-17 production are rather controversial. One study demonstrated significant tumor ablation upon adoptive transfer of tumor specific Th17-polarized cells in vivo, mediated through their production of IL-17 [184]. Another group showed similar results owing to increased recruitment of leukocytes and increased activation of tumor-specific CD8+ T cells [185]. Conversely, studies have also shown that Th-17 cells enhance melanoma tumor proliferation and survival through IL-17 production. This resulted in increased production of IL-6 by IL-17 receptor-expressing tumor and tumor-associated stromal cells and concomitantly increased STAT3 signaling and production of pro-survival Bcl-2 and Bcl-xl in melanoma cells [186]. Overexpression of eIF4E, or a constitutively active MNK1, have also been shown to increase the production of RFLAT-1, a transcriptional regulator of CCL5 in T-cells [187]. One study showed that MNK1/2 double knock out transgenic mice had no influence on the development of αβ T cells, T-regs, or natural killer T-cells (NKT) [188]. The study also demonstrated that the CD8+ T-cells from...
mice lacking MNK1/2 did not exhibit deficiencies in response to bacterial and viral infections [188]. In another study, in the context of a T-cell specific PTEN-null lymphoma model, deletion of MNK1/2 resulted in delayed onset of lymphoma, with a complete abolishment of eIF4E phosphorylation [189]. Collectively, these results suggest that inhibition of MNK1/2 promotes favorable anti-tumor conditions intrinsically, while promoting a strong anti-tumor microenvironment, and provides a clear rationale for the relevance and importance of developing MNK1/2 inhibitors.

6. Immunotherapy and Melanoma

Advances in immunotherapy have changed the landscape for the management of melanoma. In BRAF-mutated melanoma, combination immunotherapy achieved similar response rates to those achieved by BRAF and MEK targeted combination therapy [190]. However, in the immunotherapy arm, patients achieved more durable responses over time [190–192]. Recent efforts have been put into combining immunotherapy with BRAF and MEK inhibition to further prolong patient overall survival. Multiple preclinical studies have shown immense promise in combining MAPK inhibition with immunotherapy [193,194], and numerous clinical trials are underway in evaluating these combinations (Table 1). A recent phase III clinical trial evaluated the combination of atezolizumab (anti-PD-L1), cobimetinib (anti-MEK), and vemurafenib (anti-BRAF) demonstrated more durable responses and a significant increase in progression-free survival compared to cobimetinib and vemurafenib alone [195].

Recently, efforts have also been put into evaluating the role of the translation machinery in the context of anti-tumor immunity. One mode by which cancer cells escape immunosurveillance is by modulating the expression of immune suppressive markers. Cells frequently utilize the PD-1/PD-L1 axis to escape the immune system, and thus monoclonal antibodies were developed to block PD-1 or PD-L1 for the treatment of a growing list of malignancies [196,197]. Emerging studies suggest that modulating mRNA translation may be an effective method to increase the efficacy of immunotherapy. One study demonstrated that diminished translation activity decreased the expression of surface PD-L1 in melanoma [144]. Moreover, this effect could be recapitulated in vivo by pharmacologically inhibiting eIF4A [144]. When syngeneic melanoma cells were engrafted into immune competent mice, inhibition of eIF4A using silvestrol resulted in a pronounced delay in tumor growth [144]. The result was attributed to the ability of silvestrol to decrease surface PD-L1 expression and increase tumor infiltration of immune cells [144]. This effect was diminished when the same cells were engrafted into immunocompromised mice, CD8+ T-cell-depleted mice, or when PD-L1 was overexpressed in engrafted cells [144]. Similarly, regulating translation through MNK1/2 inhibition has also been credited to a direct decrease in PD-L1 expression. In an aggressive cell model of liver cancer expressing MYCTg;KRASG12D, treatment with eFT508 significantly decreased the translation of and, thereby, surface expression of PD-L1 [198]. This decrease in surface PD-L1 expression was also recapitulated when MYCTg;KRASG12D were overexpressed in cells harboring non-phosphorylatable eIF4E (eIF4E<sup>S209A/S209A</sup>) [198]. While still in their initial stages, these studies strongly indicate a link between inhibiting translation regulation and increased immune response.

| Immunotherapy Target | Immunotherapy Targeted Inhibitors | Clinical Trial Identifier | Clinical Phase | Clinical Trial Status |
|----------------------|-----------------------------------|---------------------------|----------------|----------------------|
| CTLA4                | Ipilimumab                        | NCT01440451               | Phase I        | Terminated           |
|                      | Ipilimumab + Vemurafenib          | NCT02200562               | Phase I        | Terminated           |
|                      | Ipilimumab + Dabrafenib           | NCT01767454               | Phase I        | Completed            |
|                      | Ipilimumab + Dabrafenib +trametinib| NCT03245556               | Phase I        | Completed            |

Table 1. Summary of clinical trials utilizing MAPK pathway targeted therapy in combination with checkpoint immunotherapy.
### Table 1. Cont.

| Immunotherapy Target | Targeted Inhibitors | Clinical Trial Identifier | Clinical Phase | Clinical Trial Status |
|----------------------|---------------------|---------------------------|----------------|----------------------|
| CTLA4 + PD1          |                     |                           |                |                      |
|                      | Ipilimumab;         |                           |                |                      |
|                      | Nivolumab;          |                           |                |                      |
|                      | Ipilimumab +        |                           |                |                      |
|                      | Nivolumab           |                           |                |                      |
|                      | Dabrafenib;         |                           |                |                      |
|                      | Trametinib;         |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT01940809               | Phase I        | Active, not recruiting |
|                      | Ipilimumab +        |                           |                |                      |
|                      | Nivolumab           |                           |                |                      |
|                      | Encorafenib +       |                           |                |                      |
|                      | Binimetinib         | NCT03235245               | Phase II       | Recruiting           |
|                      | Nivolumab           |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT02968303               | Phase II       | Active, not recruiting |
|                      | Ipilimumab +        |                           |                |                      |
|                      | Nivolumab           |                           |                |                      |
|                      | Encorafenib +       |                           |                |                      |
|                      | Binimetinib         | NCT02631447               | Phase II       | Active, not recruiting |
|                      | Nivolumab           |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02224781               | Phase III      | Recruiting           |
| PD-1                 | Nivolumab           |                           |                |                      |
|                      | Dabrafenib;         |                           |                |                      |
|                      | Trametinib;         |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02357732               | Phase I        | Withdrawn            |
|                      | Nivolumab           |                           |                |                      |
|                      | Dabrafenib;         |                           |                |                      |
|                      | Trametinib;         |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02910700               | Phase II       | Recruiting           |
|                      | Pembrolizumab       |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT02818023               | Phase I        | Active, not recruiting |
|                      | Pembrolizumab       |                           |                |                      |
|                      | Trametinib +        |                           |                |                      |
|                      | Dabrafenib          | NCT02130466               | Phase I/II     | Active, not recruiting |
|                      | Pembrolizumab       |                           |                |                      |
|                      | Encorafenib +       |                           |                |                      |
|                      | Binimetinib         | NCT02902042               | Phase I/II     | Recruiting           |
|                      | Pembrolizumab       |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02858921               | Phase II       | Recruiting           |
|                      | Pembrolizumab       |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02625337               | Phase II       | Unknown/Completed    |
|                      | Spartalizumab       |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | Trametinib          | NCT02967692               | Phase III      | Active, not recruiting |
| PD-L1                | Atezolizumab        |                           |                |                      |
|                      | Vemurafenib;        |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT01656642               | Phase I        | Active, not recruiting |
|                      | Atezolizumab        |                           |                |                      |
|                      | Cobimetinib         | NCT03178851               | Phase I        | Active, not recruiting |
|                      | Durvalumab (MEDI4736) | Dabrafenib;              |                |                      |
|                      | Dabrafenib;         |                           |                |                      |
|                      | Trametinib;         |                           |                |                      |
|                      | Dabrafenib +        |                           |                |                      |
|                      | trametinib          | NCT02027961               | Phase I/II     | Completed            |
|                      | Atezolizumab        |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT03554083               | Phase II       | Recruiting           |
|                      | Atezolizumab        |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT02902029               | Phase II       | Active, not recruiting |
|                      | Atezolizumab        |                           |                |                      |
|                      | Cobimetinib         | NCT01998896               | Phase I        | Completed            |
|                      | Atezolizumab        |                           |                |                      |
|                      | Vemurafenib +       |                           |                |                      |
|                      | Cobimetinib         | NCT02908672               | Phase III      | Active, not recruiting |

### 7. Conclusions

It is an exciting time to be studying MNK1 and MNK2, as potent pharmacological inhibitors of these kinases are, or have been, in clinical trials (NCT03616834, NCT02605083, NCT03690141, and NCT02439346). While a lot of questions regarding the biology of MNK1/2 remain, the wealth of literature available strongly indicates the pro-tumorigenic role of the MNK1/2-eIF4E axis in numerous cancer types, including melanoma. Further investigation is required to better understand the roles of MNK1/2 with respect to proliferation, metastasis, and the immune system.

**Author Contributions:** Design, S.A.P., O.M., and S.V.d.R.; writing, S.A.P., O.M., and S.V.d.R.; figures, O.M. and S.P.; writing—review and editing, S.V.d.R. and W.H.M.J. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research is funded by the Canadian Institutes for Health Research (grant PJT-162260 to SVDR and grant MOP-142281 to WHM) and the Canadian Cancer Society (grant 703811WHM). This work was also supported by the Terry Fox Research Institute-Montreal Cancer Consortium (TFRI-Grant #1084). The research was further supported by the Rossy Cancer Network. SP was supported by a FRQS graduate studentship.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Akbani, R.; Akdemir, K.C.; Aksoy, B.A.; Albert, M.; Ally, A.; Amin, S.; Arachchi, H.; Arora, A.; Auman, J.T.; Ayala, B.; et al. Genomic Classification of Cutaneous Melanoma. *Cell* 2015, 161, 1681–1696. [CrossRef] [PubMed]

2. Curtin, J.; Busam, K.; Pinkel, D.; Bastian, B.C. Somatic Activation of KIT in Distinct Subtypes of Melanoma. *J. Clin. Oncol.* 2006, 24, 4340–4346. [CrossRef]

3. Shoushtari, A.N.; Carvajal, R.D. GNAQ and GNA11 mutations in uveal melanoma. *Melanoma Res.* 2014, 24, 525–534. [CrossRef] [PubMed]

4. Sun, J.; Carr, M.J.; Khushalani, N.I. Principles of Targeted Therapy for Melanoma. *Surg. Clin. North Am.* 2019, 100, 175–188. [CrossRef]

5. Pratilas, C.A.; Taylor, B.S.; Ye, Q.; Viale, A.; Sander, C.; Solit, D.B.; Rosen, N. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc. Natl. Acad. Sci. USA* 2009, 106, 4519–4524. [CrossRef] [PubMed]

6. Nassar, K.W.; Tan, A.C. The mutational landscape of mucosal melanoma. *Semin. Cancer Biol.* 2020, 61, 139–148. [CrossRef]

7. Devitt, B.; Liu, W.; Salemi, R.; Wolfe, R.; Kelly, J.; Tzen, C.-Y.; Dobrovic, A.; McArthur, G. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. *Pigment. Cell Melanoma Res.* 2011, 24, 666–672. [CrossRef]

8. Jakob, J.A.; Bassett, R.L.; Ng, C.S.; Curry, J.L.; Joseph, R.W.; Alvarado, G.C.; Rohlfis, M.L.; Richard, J.; Gershenwald, J.E.; Kim, K.B.; et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. *Cancer* 2011, 118, 4014–4023. [CrossRef]

9. Babaei, M.A.; Goh, Y.-M.; Saleem, M.; Huri, H.Z.; Ahmadipour, F. Receptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells. *Drug Des. Dev. Ther.* 2016, 10, 2443–2459. [CrossRef]

10. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New Engl. J. Med.* 2011, 364, 2507–2516. [CrossRef]

11. Yang, A.S.; Chapman, P.B. The History and Future of Chemotherapy for Melanoma. *Hematol. Clin. North Am.* 2009, 23, 583–597. [CrossRef] [PubMed]

12. Sosman, J.A.; Kim, K.B.; Schuchter, L.; Gonzalez, R.; Pavlick, A.C.; Weber, J.S.; McArthur, G.; Hutson, T.E.; Moschos, S.J.; Fidely, K.T.; et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *New Engl. J. Med.* 2012, 366, 707–714. [CrossRef] [PubMed]

13. Shi, H.; Hugo, W.; Kong, X.; Hong, A.; Koya, R.C.; Moriceau, G.; Chodon, T.; Guo, R.; Johnson, D.B.; Dahlman, K.B.; et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov.* 2013, 4, 80–93. [CrossRef] [PubMed]

14. Heidorn, S.J.; Milagre, C.; Whittaker, S.R.; Noirry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.S.; Springer, C.J.; Pritchard, C.; et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. *Cell* 2010, 140, 209–221. [CrossRef] [PubMed]

15. Das Thakur, M.; Salangsang, F.; Landman, A.S.; Sellers, W.R.; Pryer, N.K.; Levesque, M.P.; Dummer, R.; McMahon, M.; Stuart, D.D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. *Nature* 2013, 494, 251–255. [CrossRef]

16. Broman, K.K.; Dossett, L.; Sun, J.; Eroglu, Z.; Zager, J.S. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. *Expert Opin. Drug Saf.* 2019, 18, 381–392. [CrossRef]

17. Larkin, J.; Ascierto, P.A.; Dréno, B.; Atkinson, V.; Liszkay, G.; Maio, M.; Mandalà, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. *New Engl. J. Med.* 2014, 371, 1867–1876. [CrossRef]

18. Long, G.V.; Hauschild, A.; Santinami, M.; Atkinson, V.; Mandalà, M.; Stili, V.C.; Larkin, J.; Nyakas, M.; Dutriaux, C.; Haydon, A.; et al. Adjuvant Dabrafenib plus Trametinib in Stage IIIIBRAF-Mutated Melanoma. *New Engl. J. Med.* 2017, 377, 1813–1823. [CrossRef]
19. Dummer, R.; Ascierto, P.A.; Gogas, H.; Arance, A.; Mandalà, M.; Liszkay, G.; Garbe, C.; Schadendorf, D.; Krajsová, I.; Gutzmer, R.; et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2018, 19, 603–615. [CrossRef]

20. Kakadia, S.; Yarlagadda, N.; Awad, R.; Kundranda, M.; Niu, J.; Naraev, B.; Mina, L.; Dragovich, T.; Gimbel, M.; Mahmoud, F. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. *Oncol. Targets Ther.* 2018, 11, 7095–7107. [CrossRef] [PubMed]

21. Smith, M.P.; Brunton, H.; Rowling, E.J.; Ferguson, J.; Arozarena, I.; Miskolczi, Z.; Lee, J.L.; Girotti, M.R.; Marais, R.; Levesque, M.P.; et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. *Cancer Cell* 2016, 29, 270–284. [CrossRef]

22. Kiuru, M.; Busam, K.J. The NF1 gene in tumor syndromes and melanoma. *Lab. Invest.* 2017, 97, 146–157. [CrossRef] [PubMed]

23. Dankort, D.; Curley, D.P.; Cartlidge, R.A.; Nelson, B.; Karnezis, A.N.; Damsky, W.E.; You, M.J.; Depinho, R.A.; McMahon, M.; Bosenberg, M.W. BrafV600E cooperates with Pten loss to induce metastatic melanoma. *Nat. Genet.* 2009, 41, 544–552. [CrossRef]

24. Singh, H.; Longo, D.L.; Chabner, B.A. Improving Prospects for Targeting RAS. *J. Clin. Oncol.* 2015, 33, 3650–3659. [CrossRef] [PubMed]

25. Gajewski, T.F.; Salama, A.K.; Niedzwiecki, D.; Johnson, J.; Linette, G.; Bucher, C.; Blaskovich, M.A.; Sebti, S.M.; Haluska, F. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). *J. Transl. Med.* 2012, 10, 246. [CrossRef] [PubMed]

26. Dummer, R.; Schadendorf, D.; Ascierto, P.A.; Arance, A.; Dutriaux, C.; di Giacomo, A.M.; Rutkowski, P.; del Vecchio, M.; Gutzmer, R.; Mandalà, M.; et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017, 18, 435–445. [CrossRef]

27. Najem, A.; Krayem, M.; Salès, F.; Hussein, N.; Badran, B.; Robert, C.; Awada, A.; Journe, F.; Ghnem, G. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. *Eur. J. Cancer* 2017, 83, 154–165. [CrossRef]

28. Nakamura, A.; Arita, T.; Tsuchiya, S.; Donelan, J.; Chouit, J.; Carideo, E.; Galvin, K.; Okaniwa, M.; Ishikawa, T.; Yoshida, S. Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. *Cancer Res.* 2013, 73, 7043–7055. [CrossRef]

29. Wong, D.J.; Robert, L.; Streti, M.; Lassen, A.; Avarappatt, G.; Cerniglia, M.; Afamasi, E.; Tsao, J.; Foulad, D.; Greber, T.; et al. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. *Mel. Cancer* 2014, 13, 194. [CrossRef]

30. Guo, J.; Carvajal, R.D.; Dummer, R.; Hauschild, A.; Daud, A.; Bastian, B.C.; Markovic, S.N.; Queirolo, P.; Arance, A.; Berking, C.; et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase II TEAM trial. *Ann. Oncol.* 2017, 28, 1380–1387. [CrossRef]

31. Guo, J.; Si, L.; Kong, Y.; Flaherty, K.T.; Xu, X.; Zhu, Y.; Corless, C.L.; Li, L.; Li, H.; Sheng, X.; et al. Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification. *J. Clin. Oncol.* 2011, 29, 2904–2909. [CrossRef] [PubMed]

32. Kalinsky, K.; Lee, S.; Rubin, K.M.; Lawrence, D.P.; Iafrate, A.J.; Borger, D.R.; Margolin, K.; Leitao, M.M.; Tarhini, A.A.; Koon, H.B.; et al. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). *Cancer* 2017, 123, 2688–2697. [CrossRef]

33. Carvajal, R.D.; Antonescu, C.R.; Wolchok, J.D.; Chapman, P.B.; Roman, R-A.; Teitche, J.; Panageas, K.S.; Busam, K.J.; Chmielowski, B.; Lutzky, J.; et al. KIT as a Therapeutic Target in Metastatic Melanoma. *JAMA* 2011, 305, 2327–2334. [CrossRef] [PubMed]

34. Han, Y.; Gu, Z.; Wu, J.; Huang, X.; Zhou, R.; Shi, C.; Tao, W.; Wang, L.; Wang, Y.; Zhou, G.; et al. Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas. *Theranostics* 2019, 9, 1952–1964. [CrossRef]
35. Casali, P.; le Cesne, A.; Velasco, A.P.; Kotasek, D.; Rutkowski, P.; Hohenberger, P.; Fumagalli, E.; Judson, I.; Italiano, A.; Gelderblom, H.; et al. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J. Clin. Oncol. 2015, 33, 4276–4283. [CrossRef] [PubMed]

36. Minor, D.R.; Kashani-Sabet, M.; Garrido, M.; O’Day, S.J.; Hamid, O.; Bastian, B.C. Sunitinib Therapy for Melanoma Patients with KIT Mutations. Clin. Cancer Res. 2012, 18, 1457–1463. [CrossRef] [PubMed]

37. Todd, J.R.; Becker, T.M.; Kefford, R.; Rizos, H. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment. Cell Melanoma Res. 2013, 26, 518–526. [CrossRef]

38. Conca, E.; Negri, T.; Gronchi, A.; Fumagalli, E.; Tamborini, E.; Pavan, G.M.; Fermeglia, M.; Pierotti, M.; Priel, S.; Pilotti, S. Activate and resist: L576P-KIT in GIST. Mol. Cancer Ther. 2009, 8, 2491–2495. [CrossRef]

39. Woodman, S.E.; Trent, J.C.; Stemke-Hale, K.; Lazar, A.; Priel, S.; Pavan, G.M.; Fermeglia, M.; Gopal, Y.V.; Yang, D.; Podoloff, N.A.; et al. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Mol. Cancer Ther. 2009, 8, 2079–2085. [CrossRef]

40. Sabnis, A.J.; Bivona, T.G. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol. Med. 2019, 25, 185–197. [CrossRef]

41. Marcotrigiano, J.; Gingras, A.-C.; Sonenberg, N.; Burley, S.K. Cap-Dependent Translation Initiation in Eukaryotes Is Regulated by a Molecular Mimic of eIF4G. Mol. Cell 1999, 3, 707–716. [CrossRef]

42. Ueda, T.; Watanabe-Fukunaga, R.; Fukuyama, H.; Nagata, S.; Fukunaga, R. Mnk2 and Mnk1 Are Essential for Constitutive and Inducible Phosphorylation of Eukaryotic Initiation Factor 4E but Not for Cell Growth or Development. Mol. Cell. Biol. 2004, 24, 6539–6549. [CrossRef] [PubMed]

43. Flynn, A.; Proud, C.G. Serine 209, Not Serine 53, Is the Major Site of Phosphorylation in Initiation Factor eIF-4E in Serum-treated Chinese Hamster Ovary Cells. J. Biol. Chem. 1995, 270, 21684–21688. [CrossRef] [PubMed]

44. Waskiewicz, A.J.; Johnson, J.C.; Penn, B.; Mahalingam, M.; Kimball, S.R.; Cooper, J. Phosphorylation of the Cap-Binding Protein Eukaryotic Translation Initiation Factor 4E by Protein Kinase Mnk1 In Vivo. Mol. Cell. Biol. 1999, 19, 1871–1880. [CrossRef] [PubMed]

45. Holm, N.; Byrnes, K.; Johnson, L.; Abreo, F.; Sehon, K.; Alley, J.; Meschonat, C.; Chu, Q.; Li, B.D.L. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer. Ann. Surg. Oncol. 2008, 15, 3207–3215. [CrossRef] [PubMed]

46. Khosravi, S.; Tam, K.J.; Ardekani, G.S.; Martinka, M.; McElwee, K.J.; Ong, C.J. EIF4E Is an Adverse Prognostic Marker of Melanoma Patient Survival by Increasing Melanoma Cell Invasion. J. Investig. Dermatol. 2015, 135, 1358–1367. [CrossRef] [PubMed]

47. Graff, J.R.; Konicek, B.W.; Lynch, R.L.; Dumstorf, C.A.; Dowless, M.S.; McNulty, A.M.; Parsons, S.H.; Brail, L.H.; Colligan, B.M.; Koop, J.W.; et al. eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival. Cancer Res. 2009, 69, 3866–3873. [CrossRef]

48. Fang, D.; Peng, J.; Wang, G.; Zhou, D.; Geng, X. Upregulation of eukaryotic translation initiation factor 4E associates with a poor prognosis in gallbladder cancer and promotes cell proliferation in vitro and in vivo. Int. J. Mol. Med. 2019, 44, 1325–1332. [CrossRef]

49. Chen, Y.-T.; Tsai, H.-P.; Wu, C.-C.; Wang, J.-Y.; Chai, C.-Y. Eukaryotic translation initiation factor 4E (eIF-4E) expressions are associated with poor prognosis in colorectal adenocarcinoma. Pathol. Res. Pr. 2017, 213, 490–495. [CrossRef]

50. Jiang, X.-M.; Yu, X.-N.; Huang, R.-Z.; Zhu, H.-R.; Chen, X.-P.; Xiong, J.; Chen, Z.-Y.; Huang, X.-X.; Shen, X.; Zhu, J.-M. Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2016, 142, 2309–2317. [CrossRef]

51. Salehi, Z.; Mashayekhi, F.; Shahhosseini, F. Significance of eIF4E expression in skin squamous cell carcinoma. Cell. Biol. Int. 2007, 31, 1400–1404. [CrossRef] [PubMed]

52. Salehi, Z.; Mashayekhi, F. Expression of the eukaryotic translation initiation factor 4E (eIF4E) and 4E-BP1 in esophageal cancer. Clin. Biochem. 2006, 39, 404–409. [CrossRef] [PubMed]
53. Wheater, M.J.; Johnson, P.W.M.; Blaydes, J.P. The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol. Ther. 2010, 10, 728–735. [CrossRef] [PubMed]

54. Konicek, B.W.; Stephens, J.R.; McNulty, A.M.; Robichaud, N.; Peery, R.B.; Dumstorf, C.A.; Dowless, M.S.; Iversen, P.W.; Parsons, S.; Ellis, K.E.; et al. Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases. Cancer Res. 2011, 71, 1849–1857. [CrossRef]

55. Fan, W.; Wang, W.; Mao, X.; Chu, S.; Feng, J.; Xiao, D.; Zhou, J.; Fan, S. Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas. J. Neuro-Oncol. 2016, 131, 485–493. [CrossRef]

56. Lu, J.; Zang, H.; Zheng, H.; Zhan, Y.; Yang, Y.; Zhang, Y.; Liu, S.; Feng, J.; Wen, Q.; Long, M.; et al. Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer. PLoS ONE 2020, 15, e0227768. [CrossRef] [PubMed]

57. Zheng, J.; Li, J.; Xu, L.; Xie, G.; Wen, Q.; Luo, J.; Li, D.; Huang, N.; Fan, S. Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma. PLoS ONE 2014, 9, e89220. [CrossRef] [PubMed]

58. Carter, J.H.; Deddens, J.; Iv, N.R.S.; Lucas, D.; Colligan, B.M.; Lewis, T.G.; Hawkins, E.; Jones, J.; O Pemberton, J.; E Douglass, L.; et al. Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma. Br. J. Cancer 2016, 114, 444–453. [CrossRef]

59. Furic, L.; Rong, L.; Larsson, O.; Koumakpayi, I.H.; Yoshida, K.; Brueschke, A.; Petroulakis, E.; Robichaud, N.; Pollak, M.; Gaboury, L.A.; et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. USA 2010, 107, 14134–14139. [CrossRef]

60. Fan, S.; Ramalingam, S.S.; Kauh, J.; Xu, Z.; Khuri, F.R.; Sun, S.-Y. Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol. Ther. 2009, 8, 1463–1469. [CrossRef]

61. Hou, S.; Du, P.; Wang, P.; Liu, P. Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer. Clin. Transl. Oncol. 2017, 21, 69–1116. [CrossRef]

62. Zhan, Y.; Guo, J.; Yang, W.; Goncalves, C.; Rzymski, T.; Dreas, A.; Żytkiewicz, E.; Mikulski, M.; Brzózka, K.; Golas, A.; et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J. Clin. Investig. 2017, 127, 4179–4192. [CrossRef] [PubMed]

63. Guo, Q. MNK1/NODAL signaling promotes invasive progression of breast ductal carcinoma in situ. Cancer Res. 2019, 79, 1646–1657. [CrossRef]

64. Agüeras, S.R.Y.C.; de Mattos-Arruda, L.; Sonenberg, N.; Cortes, J.; Peg, V. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and pElF4E are diffusely expressed and are real potential targets. Clin. Transl. Oncol. 2015, 17, 937–941. [CrossRef]

65. Truitt, M.L.; Conn, C.S.; Shi, Z.; Pang, X.; Tokuyasu, T.; Coady, A.M.; Seo, Y.; Barna, M.; Ruggero, D. Differential Requirements for eIF4E Dose in Normal Development and Cancer. Cell 2015, 162, 59–71. [CrossRef] [PubMed]

66. Welsh, S.J.; Corrie, P.G. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med Oncol. 2015, 7, 122–136. [CrossRef] [PubMed]

67. O’Loghlen, A.; González, V.M.; Piñeiro, D.; Pérez-Morgado, M.; Salinas, M.; Martin, M. Identification and molecular characterization of Mnk1b, a splice variant of human MAP kinase-interacting kinase Mnk1. Exp. Cell Res. 2004, 299, 343–355. [CrossRef]

68. Slentz-Kesler, K.; Moore, J.T.; Lombard, M.; Zhang, J.; Hollingsworth, R.; Weiner, M.P. Identification of the Human Mnk2 Gene (MKNK2) through Protein Interaction with Estrogen Receptor β. Genomics 2000, 69, 63–71. [CrossRef]

69. Fukunaga, R.; Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 1997, 16, 1921–1933. [CrossRef]

70. Scheper, G.C.; Parra, J.L.; Wilson, M.; van Kollenburg, B.; Verteagaal, A.C.O.; Han, Z.; Proud, C.G. The N and C Termini of the Splice Variants of the Human Mitogen-Activated Protein Kinase-Interacting Kinase Mnk2 Determine Activity and Localization. Mol. Cell. Biol. 2003, 23, 5692–5705. [CrossRef]

71. Parra-Palau, J.-L.; Scheper, G.C.; Wilson, M.L.; Proud, C.G. Features in the N and C Termini of the MAPK-interacting Kinase Mnk1 Mediate Its Nucleocytoplasmic Shuttlng. J. Biol. Chem. 2003, 278, 44197–44204. [CrossRef] [PubMed]
72. Pyronnet, S.; Imataka, H.; Gingras, A.-C.; Fukunaga, R.; Hunter, T.; Sonenberg, N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999, 18, 270–279. [CrossRef]
73. McKendrick, L.; Thompson, E.; Ferreira, J.; Morley, S.J.; Lewis, J.D. Interaction of Eukaryotic Translation Initiation Factor 4G with the Nuclear Cap-Binding Complex Provides a Link between Nuclear and Cytoplasmic Functions of the m7Guanosine Cap. Mol. Cell. Boil. 2001, 21, 3632–3641. [CrossRef] [PubMed]
74. Parra, J.L.; Buxade, M.; Proud, C.G. Features of the Catalytic Domains and C Termini of the MAPK Signal-integrating Kinases Mnk1 and Mnk2 Determine Their Differing Activities and Regulatory Properties. J. Biol. Chem. 2005, 280, 37623–37633. [CrossRef] [PubMed]
75. Waskiewicz, A.J.; Flynn, A.; Proud, C.G.; Cooper, J.A. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 1997, 16, 1909–1920. [CrossRef]
76. Jauch, R.; Cho, M.-K.; Jäkel, S.; Netter, C.; Schreiter, K.; Aicher, B.; Zweckstetter, M.; Jäckle, H.; Wahl, M.C. Mitogen-activated protein kinase interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO J. 2006, 25, 4020–4032. [CrossRef]
77. Kannan, S. Small molecules targeting the inactive form of the Mnk1/2 kinases. ACS Omega 2017, 2, 7881–7891. [CrossRef]
78. Karni, R.; de Stanchina, E.; Lowe, S.W.; Sinha, R.; Mu, D.; Krainer, A.R. The gene encoding the splicing factor SF2ASF is a proto-oncogene. Nat. Struct. Mol. Boil. 2007, 14, 185–193. [CrossRef]
79. Adeso, L. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 2013, 32, 2848–2857. [CrossRef]
80. Maimon, A.; Mogilevsky, M.; Shilo, A.; Golan-Gerstl, R.; Obiedat, A.; Ben-Hur, V.; Lebenthal-Loinger, I.; Stein, I.; Reich, R.; Beenstock, J.; et al. Mnk2 Alternative Splicing Modules the p38-MAPK Pathway and Impacts Ras-Induced Transformation. Cell Rep. 2014, 7, 501–513. [CrossRef]
81. Pinto, C.; García-Recio, E.M.; Pérez-Morgado, M.I.; García-Hernández, M.; Sanz-Criado, L.; Sacristán, S.; Toledo-Lobo, M.V.; Pérez-Mies, B.; Esteban-Rodriguez, I.; Pascual, A.; et al. Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer. Oncotarget 2018, 9, 13501–13516. [CrossRef] [PubMed]
82. García-Recio, E.M.; Pinto, C.; Pérez-Morgado, M.I.; García-Hernández, M.; Fernández, G.; Martín, M.; González, V.M. Characterization of MNK1b DNA Aptamers That Inhibit Proliferation in MDA-MB231 Breast Cancer Cells. Mol. Ther. Nucleic Acids 2016, 5, e275. [CrossRef] [PubMed]
83. Goto, S.; Yao, Z.; Proud, C.G. The C-terminal domain of Mnk1a plays a dual role in tightly regulating its activity. Biochem. J. 2009, 423, 279–290. [CrossRef] [PubMed]
84. Cohen, N.; Sharma, M.; Kentsis, A.; Perez, J.M.; Strudwick, S.; Borden, K.L. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J. 2001, 20, 4547–4559. [CrossRef] [PubMed]
85. Rousseau, D.; Kaspar, R.; Rosenwald, I.; Gehrke, L.; Sonenberg, N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. USA 1996, 93, 1065–1070. [CrossRef]
86. Guo, Z.; Peng, G.; Li, E.; Xi, S.; Zhang, Y.; Li, Y.; Lin, X.; Li, G.; Wu, Q.; He, J. MAP kinase-interacting serine/threonine kinase 2 promotes proliferation, metastasis, and predicts poor prognosis in non-small cell lung cancer. Sci. Rep. 2017, 7, 10612. [CrossRef]
87. Linkous, A.; Yazlovitskaya, E.M. Cytosolic phospholipase A2 as a mediator of disease pathogenesis. Cell. Microbiol. 2010, 12, 1369–1377. [CrossRef]
88. Hefner, Y.; Borsch-Haubold, A.G.; Murakami, M.; Wilde, J.I.; Pasquet, S.; Schieltz, D.; Ghomashchi, F.; Yates, I.J.R.; Armstrong, C.G.; Paterson, A.; et al. Serine 727 Phosphorylation and Activation of Cytosolic Phospholipase A2b by MNK1-related Protein Kinases. J. Boil. Chem. 2000, 275, 37542–37551. [CrossRef]
89. Buxade, M.; Morrice, N.; Krebs, D.L.; Proud, C.G. The PSF [middle dot] p54nrb Complex Is a Novel Mnk Substrate That Binds the mRNA for Tumor Necrosis Factor. J. Boil. Chem. 2007, 283, 57–65. [CrossRef]
90. Mitobe, Y.; Inoue, S. PSF promotes ER-positive breast cancer progression via posttranscriptional regulation of ESR1 and SCFD2. Cancer Res. 2020. [CrossRef]
91. Tsukahara, T.; Haniu, H.; Matsuda, Y. PTB-associated splicing factor (PSF) is a PPARgamma-binding protein and growth regulator of colon cancer cells. PLoS One 2013, 8, e58749. [CrossRef] [PubMed]
92. Tsukahara, T.; Matsuda, Y.; Hanitou, H. PSF Knockdown Enhances Apoptosis via Downregulation of LC3B in Human Colon Cancer Cells. *BioMed Res. Int.* 2013, 1–8. [CrossRef] [PubMed]

93. Buxadé, M.; Parra, J.L.; Rousseau, S.; Shpiro, N.; Marquez, R.; Morrice, N.; Bain, J.; Espel, E.; Proud, C.G. The Mnks Are Novel Components in the Control of TNFα Biosynthesis and Phosphorylate and Regulate hnrNPA1. *Immunity* 2005, 23, 177–189. [CrossRef] [PubMed]

94. Roy, R.; Huang, Y.; Scekla, M.J.; Pardo, O.E. Emerging roles of hnRNPA1 in modulating malignant transformation. *Wiley Interdiscip. Rev. RNA* 2017, 8, e1431. [CrossRef] [PubMed]

95. Chen, Y.; Liu, J.; Wang, W.; Xiang, L.; Wang, J.; Liu, S.; Zhou, H.; Guo, Z. High expression of hnRNPA1 promotes cell invasion by inducing EMT in gastric cancer. *Oncol. Rep.* 2018, 39, 1693–1701. [CrossRef] [PubMed]

96. Edwin, F.; Anderson, K.; Patel, T.B. HECT Domain-containing E3 Ubiquitin Ligase Nedd4 Interacts with and Ubiquinates Sprouty2. *J. Biol. Chem.* 2009, 284, 255–264. [CrossRef]

97. Da Silva, J.; Xu, L.; Kim, H.J.; Miller, W.T.; Bar-Sagi, D. Regulation of Sprouty Stability by Mnk1-Dependent Phosphorylation. *Mol. Cell. Biol.* 2006, 26, 1898–1907. [CrossRef]

98. Park, J.-W.; Wollmann, G.; Urbiola, C.; Fogli, B.; Florio, T.; Geley, S.; Klimaschewski, L. Sprouty2 enhances transformation. *Oncogene* 2005, 24, 5435–5445. [CrossRef]

99. Saini, M.; Verma, A.; Mathew, S. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma. *Cell Death Dis.* 2018, 9, 237. [CrossRef]

100. Lam, D.; Verma, C.S. Deciphering the mechanistic effects of eIF4E phosphorylation on mRNA-cap recognition. *Protein Sci.* 2019, 28, 1373–1386. [CrossRef]

101. Marcoitrigiano, J.; Gingras, A.-C.; Sonenberg, N.; Burley, S.K. Cocrystal Structure of the Messenger RNA 5' Cap-Binding Protein (eIF4E) Bound to 7-methyl-GDP. *Cell* 1997, 89, 951–961. [CrossRef]

102. Schepers, G.C.; van Kollenburg, B.; Hu, J.; Luo, Y.; Goss, D.J.; Proud, C.G. Phosphorylation of Eukaryotic Initiation Factor 4E Markedly Reduces Its Affinity for Capped mRNA. *J. Biol. Chem.* 2001, 277, 3303–3309. [CrossRef] [PubMed]

103. Slepenkov, S.V.; Darzynkiewicz, E.; Rhoads, R.E. Stopped-flow Kinetic Analysis of eIF4E and Phosphorylated eIF4E Binding to Cap Analogos and Capped Oligoribonucleotides. *J. Biol. Chem.* 2006, 281, 14927–14938. [CrossRef] [PubMed]

104. Topisirovic, I.; Ruiz-Gutierrez, M.; Borden, K.L.B. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. *Cancer Res.* 2004, 64, 8639–8642. [CrossRef]

105. Robichaud, N.; del Rincon, S.V.; Huor, B.; Alain, T.; A Petruccelli, L.; Hearnden, J.; Goncalves, C.; Grotegut, S.; Sprack, C.H.; Furic, L.; et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. *Oncogene* 2014, 34, 2032–2042. [CrossRef]

106. Lim, S.; Saw, T.Y.; Zhang, M.; Janes, M.R.; Nacro, K.; Hill, J.; Lim, A.Q.; Chang, C.-T.; Fruman, D.A.; Rizzieri, D.A.; et al. Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. *Proc. Natl. Acad. Sci. USA* 2013, 110, 2298–2307. [CrossRef]

107. Geter, P.A.; Ernland, A.W.; Bakogiani, S.; Alard, A.; Arju, R.; Giashuddin, S.; Gadi, A.; Bromberg, J.; Schneider, R.J. Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. *Genome Res.* 2017, 31, 2235–2249. [CrossRef]

108. Robichaud, N.; Hsu, B.E.; Istomine, R.; Alvarez, F.; Blagih, J.; Ma, E.H.; Morales, S.V.; Dai, D.L.; Li, G.; Souleimanova, M.; et al. Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils. *Proc. Natl. Acad. Sci. USA* 2018, 115, 2202–2209. [CrossRef]

109. Eberle, J.; Krasagakis, K.; Orfanos, C.E. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. *Int. J. Cancer* 1997, 71, 396–401. [CrossRef]

110. Yang, S.X.; Hewitt, S.M.; Steinberg, S.M.; Liewehr, D.J.; Swain, S. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. *Oncol. Rep.* 2007, 17, 281–287. [CrossRef]

111. De Benedetti, A.; Joshi-Barve, S.; Rinker-Schaeffer, C.; Rhoads, R.E. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in strengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. *Mol. Cell. Biol.* 1991, 11, 5435–5445. [CrossRef] [PubMed]
112. De Fatta, R.J.; Nathan, C.-A.O.; De Benedetti, A. Antisense RNA to eIF4E Suppresses Oncogenic Properties of a Head and Neck Squamous Cell Carcinoma Cell Line. *Laryngoscope* **2000**, *110*, 928–933. [CrossRef] [PubMed]

113. Graff, J.R.; Kopicke, B.W.; Vincent, T.M.; Lynch, R.L.; Monteieth, D.; Weir, S.N.; Schwier, P.; Capen, A.; Goode, R.L.; Dowless, M.S.; et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. *J. Clin. Investig.* **2007**, *117*, 2638–2648. [CrossRef] [PubMed]

114. Rinker-Schaeffer, C.W.; Graff, J.R.; De Benedetti, A.; Zimmer, S.G.; Rhoads, R.E. Decreasing the level of translation initiation factor 4E with antisense ma causes reversal ofras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. *Int. J. Cancer* **1993**, *55*, 841–847. [CrossRef]

115. Jiang, C.C.; Croft, A.; Tseng, H.-Y.; Guo, S.T.; Jin, L.; Hersey, P.; Zhang, X.D. Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. *Oncogene* **2013**, *33*, 2577–2588. [CrossRef]

116. Wendel, H.-G. Dissecting elf4E action in tumorigenesis. *Genes Dev.* **2007**, *21*, 3232–3237. [CrossRef]

117. Wen, Y.; Lai, F.; Tseng, H.-Y.; Guo, S.T.; Jin, L.; Hersey, P.; Zhang, X.D. Requirement of RNA Binding by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. *Oncogene* **2013**, *33*, 2577–2588. [CrossRef]

118. Li, S.; Jia, Y.; Jacobson, B.; McCauley, J.; Kratzke, R.A. Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. *Investig. New Drugs* **2014**, *32*, 598–603. [CrossRef] [PubMed]

119. Braziunas, J. In *D74*. Molecular Targets and Model Therapies for Lung Cancer A6291–A6291. [CrossRef]

120. Li, S.; Jia, Y.; Jacobson, B.; McCauley, J.; Kratzke, R.A. Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells. *Investig. New Drugs* **2014**, *32*, 598–603. [CrossRef] [PubMed]

121. De Fatta, R.J.; Nathan, C.-A.O.; De Benedetti, A. Antisense RNA to eIF4E Suppresses Oncogenic Properties of a Head and Neck Squamous Cell Carcinoma Cell Line. *Laryngoscope* **2000**, *110*, 928–933. [CrossRef] [PubMed]

122. De Fatta, R.J.; Nathan, C.-A.O.; De Benedetti, A. Antisense RNA to eIF4E Suppresses Oncogenic Properties of a Head and Neck Squamous Cell Carcinoma Cell Line. *Laryngoscope* **2000**, *110*, 928–933. [CrossRef] [PubMed]

123. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Reibarkh, M.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.; Choye, M.; et al. Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G. *ACS Chem. Boil.* **2009**, *3*, 367–377. [CrossRef]

124. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Reibarkh, M.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.; Choye, M.; et al. Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G. *ACS Chem. Boil.* **2009**, *3*, 367–377. [CrossRef]

125. Yanagiya, A.; Svitkin, Y.V.; Shibata, S.; Mikami, S.; Imataka, H.; Sonenberg, N. Requirement of RNA Binding of Mammalian Eukaryotic Translation Initiation Factor 4GI (eIF4GI) for eIF4G Interaction of elf4E with the mRNA Cap. *Mol. Cell. Boil.* **2008**, *29*, 1661–1669. [CrossRef]

126. Cencic, R.; Desforges, M.; Hall, D.R.; Kozakov, D.; Du, Y.; Min, J.; Dingledine, R.; Fu, H.; Vajda, S.; Talbot, P.; et al. Blocking elf4E-elf4G Interaction as a Strategy To Impair Coronavirus Replication. *J. Virol.* **2011**, *85*, 6381–6389. [CrossRef]

127. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.; Choye, M.; et al. Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G. *Cell* **2007**, *128*, 257–267. [CrossRef]

128. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.; Choye, M.; et al. Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G. *Cell* **2007**, *128*, 257–267. [CrossRef]

129. Croft, A.; Tay, K.H.; Boyd, S.C.; Guo, S.T.; Jiang, C.C.; Lai, F.; Tseng, H.-Y.; Jin, L.; Rizos, H.; Hersey, P.; et al. Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. *J. Investig. Dermatol.* **2014**, *134*, 488–497. [CrossRef]

130. Feng, Y.; Pinkerton, A.B.; Hulea, L.; Zhang, T.; Davies, M.A.; Grotegut, S.; Cheli, Y.; Yin, H.; Lau, E.L.; Kim, H.; et al. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the elf4F Translation Initiation Complex. *Cancer Res.* **2015**, *75*, 5211–5218. [CrossRef]
131. Cai, W.; Ye, Q.; She, Q.-B. Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. *Oncotarget* 2014, 5, 6015–6027. [CrossRef] [PubMed]

132. Shuda, M.; Kondeh, N.; Tanaka, K.; Ryo, A.; Wakatsuki, T.; Hada, A.; Goseki, N.; Igari, T.; Hatsuse, K.; Aihara, T.; et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. *Anticancer Res.* 2000, 20, 2489–2494. [PubMed]

133. Matsuhashi, S.; Manirujjaman, M.; Hamajima, H.; Ozaki, I. Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions. *Int. J. Mol. Sci.* 2019, 20, 2304. [CrossRef] [PubMed]

134. Suzuki, C.; Garcés, R.G.; Edmonds, K.A.; Hiller, S.; Hyberts, S.G.; Marintchev, A.; Wagner, G. PDCD4 inhibits translation initiation by binding to elf4A using both its MA3 domains. *Proc. Nat. Acad. Sci. USA* 2008, 105, 3274–3279. [CrossRef] [PubMed]

135. Sadlish, H.; Vazquez, G.G.; Paris, C.G.; Aust, T.; Bhullar, B.; Chang, L.; Helliwell, S.B.; Hoepfner, D.; Knapp, B.; Riedl, R.; et al. Evidence for a Functionally Relevant Rocaglamide Binding Site on the elf4A–RNA Complex. *ACS Chem. Bioi.* 2013, 8, 1519–1527. [CrossRef]

136. Iwasaki, S.; Iwasaki, W.; Sakamoto, A.; Watanabe, C.; Shichino, Y.; Floor, S.; Fujiwara, K.; Mito, M.; Dodo, K.; et al. The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between elf4A and Polypurine RNA. *Mol. Cell.* 2019, 73, 738–748. [CrossRef]

137. Polier, G.; Neumann, J.; Thuaud, F.; Ribeiro, N.; Gelhaus, C.; Schmidt, H.; Giaisi, M.; Köhler, R.; Müller, W.W.; Proksch, P.; et al. The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2. *Chem. Bioi.* 2012, 19, 1093–1104. [CrossRef]

138. Hawkins, B.C.; Lindqvist, L.M.; Nhu, D.; Sharp, P.P.; Segal, D.; Powell, A.; Campbell, M.; Ryan, E.; Chambers, J.M.; White, J.M.; et al. Simplified Silvestrol Analogues with Potent Cytotoxic Activity. *ChemMedChem* 2019, 4, 1556–1566. [CrossRef]

139. Hwang, B.Y.; Su, B.-N.; Chai, H.; Mi, Q.; Kardono, L.B.S.; Afriastini, J.J.; Riswan, S.; Santarsiero, B.D.; Mesecar, A.D.; Wild, R.; et al. Silvestrol and Episilvestrol, Potential Anticancer Rocaglate Derivatives fromAglaia silvestris. *J. Org. Chem.* 2004, 69, 3350–3358. [CrossRef]

140. Chen, W.-L.; Pan, L.; Kinghorn, A.D.; Swanson, S.M.; Burdette, J.E. Silvestrol induces early autophagy and apoptosis in human melanoma cells. *BMC Cancer* 2016, 16, 17. [CrossRef]

141. Chen, W.-L.; Pan, L.; Kinghorn, A.D.; Swanson, S.M.; Burdette, J.E. Silvestrol induces early autophagy and apoptosis in human melanoma cells. *BMC Cancer* 2016, 16, 17. [CrossRef]

142. Chen, W.-L.; Pan, L.; Kinghorn, A.D.; Swanson, S.M.; Burdette, J.E. Silvestrol induces early autophagy and apoptosis in human melanoma cells. *BMC Cancer* 2016, 16, 17. [CrossRef]

143. Boussemart, L.; Malka-Mahieu, H.; Girault, I.; Allard, D.; Hemmingsson, O.; Tomasic, G.; Thomas, M.; Basmadjian, C.; Ribeiro, N.; Thuaud, F.; et al. elf4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. *Nature* 2014, 513, 105–109. [CrossRef] [PubMed]

144. Malka-Mahieu, H.; Girault, I.; Rubington, M.; Leriche, M.; Welsch, C.; Kamsu-Kom, N.; Zhao, Q.; Desaubry, L.; Vagner, S.; Robert, C. Synergistic effects of elf4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. *Cell Cycle* 2016, 15, 2405–2409. [CrossRef] [PubMed]

145. Cerezo, M.; Guemiri, R.; Druillennec, S.; Girault, I.; Malka-Mahieu, H.; Shen, S.; Allard, D.; Martineau, S.; Welsch, C.; Agoussi, S.; et al. Translational control of tumor immune escape via the elf4F–STAT1–PD-L1 axis in melanoma. *Nat. Med.* 2018, 24, 1877–1886. [CrossRef]

146. Gupta, S.V. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. *AAPS J.* 2011, 13, 357. [CrossRef]

147. Thompson, P.A.; Young, N.P.; Strumpf, C.R.; Eam, B.; Goel, V.K.; Chen, J.; Fish, S.; Parker, G.S.; Gerson-Gurwitz, A.; Barrera, M.; et al. Abstract B133: eFT226, a first in class inhibitor of elf4A1, targets FGFR1/2 and HER2 driven cancers. *AACR* 2019, 18, 12.

148. Young, N.P.; Craig, R.S.; Chen, J.; Chiang, G.G.; Thompson, P.A.; Webster, K.R. A focused CRISPR screen to identify synthetic lethal interactions with the novel elf4A inhibitor eFT226 in KRAS driven NSCLC. *AACR* 2019, 79, 13.

149. Bordeleau, M.-E.; Matthews, J.; Wojnar, J.M.; Lindqvist, L.; Novac, O.; Jankowsky, E.; Sonenberg, N.; Northcote, P.; Teesdale-Spittle, P.; Pelletier, J. Stimulation of mammalian translation initiation factor elf4A activity by a small molecule inhibitor of eukaryotic translation. *Proc. Nat. Acad. Sci. USA* 2005, 102, 10460–10465. [CrossRef]
149. Low, W.-K.; Dang, Y.; Schneider-Poetsch, T.; Shi, Z.; Choi, N.S.; Merrick, W.C.; Romo, D.; Liu, J.O. Inhibition of Eukaryotic Translation Initiation by the Marine Natural Product Pateamine A. *Mol. Cell* 2005, 20, 709–722. [CrossRef]

150. Kuznetsov, G.; Xu, Q.; Rudolph-Owen, L.; Ten Dyke, K.; Liu, J.; Towle, M.; Zhao, N.; Marsh, J.; Agoulnik, S.; Twine, N.; et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. *Mol. Cancer Ther.* 2009, 8, 1250–1260. [CrossRef]

151. Bordeleau, M.-E.; Mori, A.; Oberer, M.; Lindqvist, L.; Chard, L.; Higa, T.; Belsham, G.J.; Wagner, G.; Tanaka, J.; Pelletier, J. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. *Nat. Methods* 2006, 2, 213–220. [CrossRef] [PubMed]

152. Liwak, U.; Thakor, N.; Jordan, L.E.; Roy, R.; Lewis, S.M.; Pardo, O.E.; Seckl, M.; Holcik, M. Tumor Suppressor PDCD4 Represses Internal Ribosome Entry Site-Mediated Translation of Antiapoptotic Proteins and Is Regulated by S6 Kinase 2. *Mol. Cell. Biol.* 2012, 32, 1818–1829. [CrossRef] [PubMed]

153. Carayol, N.; Katsoulidis, E.; Sassano, A.; Altman, J.K.; Druker, B.J.; Platanias, L.C. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. *J. Biol. Chem.* 2008, 283, 8601–8610. [CrossRef]

154. Yang, C.H.; Yue, J.; Pfeffer, S.R.; Handorf, C.R.; Pfeffer, L. MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells. *J. Biol. Chem.* 2011, 286, 39172–39178. [CrossRef] [PubMed]

155. Lelli, D.; Pedone, C.; Sahebkar, A. Curcumin and treatment of melanoma: The potential role of microRNAs. *Biomed. Pharmacother.* 2017, 88, 832–834. [CrossRef]

156. Yang, C.H.; Yue, J.; Sims, M.; Pfeffer, L. The Curcumin Analog EF24 Targets NF-κB and miRNA-21, and Has Potent Anticancer Activity In Vitro and In Vivo. *PLoS ONE* 2013, 8, e71130. [CrossRef]

157. Alain, T.; Morita, M.; Fonseca, B.D.; Yanagiya, A.; Siddiqui, N.; Bhat, M.; Zammit, D.; Marcus, V.; Metrakos, P.; Voyer, L.-A.; et al. eIF4E/eIF4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies. *Cancer Res.* 2012, 72, 6468–6476. [CrossRef]

158. Hsu, P.P.; Kang, S.A.; Rameseder, J.; Zhang, Y.; Ottina, K.A.; Lim, D.; Peterson, T.R.; Choi, Y.; Gray, N.S.; Yaffe, M.B.; et al. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling. *Science* 2011, 332, 1317–1322. [CrossRef]

159. Yu, Y.; Yoon, S.-O.; Poulogiannis, G.; Yang, Q.; Ma, X.M.; Villen, J.; Kubica, N.; Hoffman, G.R.; Cantley, L.C.; Gygi, S.P.; et al. Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling. *Science* 2011, 332, 1322–1326. [CrossRef]

160. Choo, A.Y.; Blenis, J. Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy. *Cell Cycle* 2009, 8, 567–572. [CrossRef]

161. Harrington, L.S.; Findlay, G.M.; Lamb, R.F. Restraining PI3K: mTOR signalling goes back to the membrane. *Trends Biochem. Sci.* 2005, 30, 35–42. [CrossRef] [PubMed]

162. Yoshizawa, A.; Fukuoka, J.; Shimizu, S.; Shilo, K.; Franks, T.J.; Hewitt, S.M.; Fujii, T.; Cordon-Cardo, C.; Jen, J.; Travis, W.D. Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer. *Clin. Cancer Res.* 2009, 16, 240–248. [CrossRef] [PubMed]

163. Martinez-Saez, E.; Peg, V.; Ortega-Aznar, A.; Martinez-Ricarte, F.; Camacho, J.; Hernández-Losa, J.; Piñas, J.C.F.; Agüeras, S.R.Y.C. peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas. *Cancer Med.* 2016, 5, 2501–2512. [CrossRef] [PubMed]

164. Ramalingam, S. The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. *Cancers* 2019, 11, 299. [CrossRef] [PubMed]

165. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C.J.; Mclachlan, H.; Klevernic, I.; Arthur, J.S.C.; Alessi, D.R.; Cohen, P. The selectivity of protein kinase inhibitors: A further update. *Biochem. J.* 2007, 408, 297–315. [CrossRef] [PubMed]

166. Yang, W.; Khoury, E.; Guo, Q.; Prabhu, S.A.; Emond, A.; Huang, F.; Gonçalves, C.; Zhan, Y.; Plourde, D.; Nichol, J.N.; et al. MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. *Oncogene* 2020, 39, 3650–3665. [CrossRef] [PubMed]

167. Kosciuczuk, E.M.; Kar, A.K.; Blyth, G.T.; Fischietti, M.; Abedin, S.; Mina, A.A.; Siliezar, R.; Rzymski, T.; Brzozka, K.; Eklund, E.A.; et al. Inhibitory effects of SEL201 in acute myeloid leukemia. *Oncotarget* 2019, 10, 7112–7121. [CrossRef]
168. Lock, R.; Ingraham, R.; Maertens, O.; Miller, A.L.; Weledji, N.; Legius, E.; Konicek, B.M.; Yan, S.-C.B.; Graff, J.R.; Cichowski, K. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J. Clin. Investig. 2016, 126, 2181–2190. [CrossRef]

169. Cherian, J.; Nacro, K.; Poh, Z.Y.; Guo, S.; Jeyaraj, D.A.; Wong, Y.X.; Ho, M.; Yang, H.Y.; Joy, J.K.; Kwek, Z.P.; et al. Structure–Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells. J. Med. Chem. 2016, 59, 3063–3078. [CrossRef]

170. Diab, S.A.H.; Abdelaziz, A.M.; Li, P.; Teo, T.; Basnet, S.K.; Noll, B.; Rahaman, M.H.; Lu, J.; Hou, J.; Yu, M.; et al. Dual Inhibition of MNK2 and FLT3 for potential treatment of acute myeloid leukemia. Eur. J. Med. Chem. 2017, 139, 762–772. [CrossRef]

171. Li, P.; Diab, S.A.H.; Yu, M.; Adams, J.; Islam, S.; Basnet, S.K.C.; Albrecht, H.; Milne, R.; Wang, S. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget 2016, 7, 56811–56825. [CrossRef] [PubMed]

172. Lineham, E.; Tizzard, G.J.; Coles, S.J.; Spencer, J.; Morley, S.J. Synergistic effects of inhibiting the MNK-eIF4E and PI3K/AKT/mTOR pathways on cell migration in MDA-MB-231 cells. Oncotarget 2018, 9, 14148–14159. [CrossRef] [PubMed]

173. Eckerdt, F.; Beauchamp, E.; Bell, J.; Iqbal, A.; Su, B.; Fukunaga, R.; Lulla, R.R.; Goldman, S.; Platanias, L.C. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget 2014, 5, 8442–8451. [CrossRef] [PubMed]

174. Grzmił, M.; Huber, R.M.; Hess, D.; Frank, S.; Hynx, D.; Moncayo, G.; Klein, M.; Merlo, A.; A Hemmings, B. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas. J. Clin. Investig. 2014, 124, 742–754. [CrossRef] [PubMed]

175. Marzec, M.T.; Liu, X.; Wysocka, M.; Rook, A.H.; Odum, N.; A Wasik, M. Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells. PLoS ONE 2011, 6, e24849. [CrossRef] [PubMed]

176. Huang, X.-B.; Yang, C.-M.; Han, Q.-M.; Ye, X.; Lei, W.; Qian, W.-B. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: The mechanism of synergic killing of human T-ALL cells. Acta Pharmacol. Sin. 2018, 39, 1894–1901. [CrossRef] [PubMed]

177. Santag, S.; Siegel, F.; Wengner, A.M.; Lange, C.; Bömer, U.; Eis, K.; Pühler, F.; Lienau, P.; Bergemann, L.;Michels, M.; et al. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity. Cancer Lett. 2017, 390, 21–29. [CrossRef]

178. Santag, S.; Siegel, F.; Wegner, A.M.; Schneider, C.; Boemer, U.; Eis, K.; Puehler, F.; Michels, M.; von Nussbaum, F.; Ziegelbauer, K.; et al. Preclinical anti-tumor efficacy and mode of action of a novel, orally bioavailable, selective MNK1 inhibitor [BAY 1143269]. AACR 2015, 75, 15.

179. Hubbard, J.M.; Patel, M.R.; Bekaii-Saab, T.; Falchook, G.S.; Freilich, B.L.; Dasari, A.; Knisely, B.T.; Anderson, M.; Chiang, G.G.; Webster, K.R.; et al. A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite unstable colorectal cancer (MSS CRC). Blood 2016, 118, 3290–3300. [CrossRef] [PubMed]

180. Osorio, C.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.; Touloukian, C.E.; Ptak, K.; et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112, 362–373. [CrossRef] [PubMed]
185. Martin-Orozco, N.; Muranski, P.; Chung, Y.; Yang, X.O.; Yamazaki, T.; Lu, S.; Hwu, P.; Restifo, N.P.; Overwijk, W.W.; Dong, C. T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. *Immunity* **2009**, *31*, 787–798. [CrossRef]

186. Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D.M.; Zeng, D.; Yu, H. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. *J. Exp. Med.* **2009**, *206*, 1457–1464. [CrossRef]

187. Nikolcheva, T. A translational rheostat for RFLAT-1 regulates RANTES expression in T lymphocytes. *J. Clin. Investig.* **2002**, *110*, 119–126. [CrossRef]

188. Gorentla, B.K.; Krishna, S.; Shin, J.; Inoue, M.; Shinozuka, M.; Grayson, J.M.; Fukunaga, R.; Zhong, X.-P. Mnk1 and 2 are dispensable for T cell development and activation but important for the pathogenesis of experimental autoimmune encephalomyelitis. *J. Immunol.* **2012**, *190*, 1026–1037. [CrossRef]

189. Ueda, T.; Sasaki, M.; Elia, A.J.; Chio, I.C.; Hamada, K.; Fukunaga, R.; Mak, T.W. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. *Proc. Nat. Acad. Sci. USA* **2010**, *107*, 13984–13990. [CrossRef]

190. Atkins, M.B.; Tarhini, A.; Rael, M.; Gupte-Singh, K.; O’Brien, E.; Ritchings, C.; Rao, S.; McDermott, D.F. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison. *Immunotherapy* **2019**, *11*, 617–629. [CrossRef]

191. Hodi, F.S.; Sileni, V.C.; Gonzalez, R.; Grob, J.-J.; Rutkowski, P.; Cowey, C.L.; Lao, C.D.; Schaden, D.; Wagstaff, J.; Dummer, R.; et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol.* **2018**, *19*, 1480–1492. [CrossRef]

192. Hodi, F.S.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.F.; McDermott, D.F.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwal, S.S.; et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol.* **2016**, *17*, 1558–1568. [CrossRef]

193. Hu-Lieskovan, S.; Mok, S.; Moreno, B.H.; Tsoi, J.; Robert, L.; Goedert, L.; Pinheiro, E.M.; Koya, R.C.; Graeber, T.; Comin-Anduix, B.; et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600Emelanoma. *Sci. Transl. Med.* **2015**, *7*, 279ra41. [CrossRef] [PubMed]

194. Cooper, Z.A.; Juneja, V.R.; Sage, P.T.; Frederick, D.T.; Piris, A.; Mitra, D.; Lo, J.A.; Hodi, F.S.; Freeman, G.J.; Rosenberg, M.W.; et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. *Cancer Immunol. Res.* **2014**, *2*, 643–654. [CrossRef]

195. McArthur, G.S.; Stroyakovskiy, D.; Gogas, H.; Robert, C.; Lewis, K.; Protsenko, S.; Pereira, R.; Eigentler, T.; Rutkowski, P.; Demidov, L.; et al. CT012 - Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (B) in previously untreated patients with BRAFV600-mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial. In Proceedings of the AACR Virtual Annual Meeting, 22–24 June 2020; online.

196. Gonzalez, H.; Hagerling, C.; Werb, Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. *Genome Res.* **2018**, *32*, 1267–1284. [CrossRef]

197. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Hong, P.; Ho, T.S.; et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. *Science* **2015**, *348*, 124–128. [CrossRef]

198. Xu, Y.; Poggio, M.; Jin, H.Y.; Shi, Z.; Forster, C.M.; Wang, Y.; Stumpf, C.R.; Xue, L.; Devericks, E.; So, L.; et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. *Nat. Med.* **2019**, *25*, 301–311. [CrossRef]